Solid dosage form production

By combining 3D printers, build platforms, and computer-controlled equipment, the complexity and stability issues of solid dosage form production in existing technologies have been solved, enabling high-resolution, customized solid dosage form production suitable for personalized treatment of pharmaceuticals, nutritional products, and food supplements.

CN118906457APending Publication Date: 2024-11-08UNIVERSITY OF CENTRAL LANCASHIRE
View PDF 3 Cites 0 Cited by

Patent Information

Application Number
CN202411184911.4
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2016-07-25
Filing Date
2017-07-25
Publication Date
2024-11-08

AI Technical Summary

Technical Problem

Existing technologies for preparing solid dosage forms suffer from problems such as high production complexity, user-unfriendly nature, large manufacturing errors, difficulty in quality control, low regulatory feasibility, and poor drug stability. In particular, in 3D printing systems, it is difficult to achieve approval of multi-dose drug products and customized treatment.

Method used

Using a device that includes a 3D printer, a build platform, and a computer, a shell composition is printed through a structural printing nozzle and a core composition is dispensed through a non-structural dispenser. Combined with computer control, this enables precise printing and customized production of solid dosage forms.

Benefits of technology

It enables high-resolution, robust solid dosage form production, reduces the risk of decomposition of heat-sensitive active ingredients, expands the scope of application, supports personalized and customized drug release profiles, and improves production efficiency and quality control.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118906457A_ABST
    Figure CN118906457A_ABST
Patent Text Reader

Abstract

The present disclosure relates to the production of solid dosage forms. The present disclosure utilizes 3D printing techniques in combination with solid and / or liquid dispensers, in particular FFF 3D printing, to produce solid dosage forms, such as drug capsules. Such solid dosage forms have a 3D printed shell and a dispensed core.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] This application is a divisional application of an application filed on July 25, 2017, with application number 201780058276.7 and invention name “Solid Dosage Form Production”.

[0002] introduction

[0003] The present invention relates to a solid dosage form printing apparatus (and a method of using the same) in the production of solid dosage forms such as capsules. The present invention also relates to solid dosage forms obtainable by such printing methods and apparatus, solid dosage form packages, related materials and printing elements (and processes for making the same), kits of parts, computers for controlling the related printing processes (and software and computer-implemented methods connected thereto), systems for collecting data related to the solid dosage form production process (and databases associated therewith), and related blueprints for use in the printing of solid dosage forms. background

[0005] The production and consumption of pharmaceuticals, nutraceuticals and food supplements (collectively referred to herein as "healthcare dosage forms") in solid dosage forms (e.g., tablets, implants, etc.) is increasing, especially due to the increased reliance on such products by the National Health Service and similar services in an increasingly health-conscious society. Where possible, solid dosage forms tend to be the most preferred over other formulations (e.g., injectable liquid formulations) due to their ease of administration (i.e., usually oral), which results in better patient compliance, storability and transportability (low space requirements and ease of packaging), high stability (longer life - less degradation). However, despite the significant advantages of solid dosage forms over other dosage forms, they are generally more cumbersome to manufacture (in terms of both the number of ingredients and processing steps), and are generally only cost-effective for large-scale production, which means that large manufacturing facilities with sophisticated equipment are generally required. These manufacturing limitations have a deleterious effect on consumer choice and / or the customizability of healthcare dosage forms because, for example, it is impractical and non-cost-effective to mass-produce a variety of different doses for a given drug via conventional manufacturing techniques. Therefore, consumers (eg, patients) and healthcare professionals (eg, physicians, pharmacists) must make the best use of a limited variety of available dosages as dictated by the supplier rather than the needs of the consumer.

[0006] Since the emergence of three-dimensional (3D) printing in the early 1980s, many researchers have tried to make health care solid dosage forms using 3D printing technology. For example, for more than ten years, MIT and Therics Inc. have collaborated to develop a feasible pill printing machine that uses a 3D printer to print solid drug dosage forms on site. The technology forms pills via a multi-layer 3D printing process that involves accurately printing the dosage of a liquid drug solution onto a thin layer of fine powder before applying additional layers (e.g., additional powders, adhesives, etc.). Examples of such processes are disclosed in early publications, such as WO95 / 11007 (MASSACHUSETTS INSTITUTE OF TECHNOLOGY) and WO03 / 092633 (THERICS, INC.), which particularly describe the production of solid dosage forms with various structures and drug release profiles. However, regulatory approval for such 3D drug printing systems (e.g., by the FDA or MHRA) remains elusive, and they are currently only suitable for low-dose drug products, in part due to the limited solubility of many drugs in the relevant ink solutions. Therefore, the patient's choice will still be very limited, as will the doctor's or pharmacist's choice in providing specially customized treatments. In addition, the resolution and shape of solid dosage forms remain problematic. However, a particular problem with prior art 3D printing systems such as these is that the large number of different ingredients (and therefore different print boxes, etc.) required to produce viable dosage forms creates a high degree of complexity and user unfriendliness, which in turn increases the possibility of manufacturing errors, machine failures and malfunctions, quality control changes, and regulatory feasibility (i.e., the FDA is unlikely to approve drug printing systems that are prone to too many variables, which may affect the quality of drug products). Another problem is the poor stability of some drug substances, particularly in liquid ink formulations. This may severely limit the shelf life of drug sources, thus causing large regulatory and cost issues.

[0007] Efforts have also been made to develop powder-based 3D printing to produce solid dosage forms with different drug release profiles. However, such techniques have various disadvantages, including: the need for dry powders, extended processing time, weak tablets that are prone to disintegration, poor resolution and poor shape control, and limited control of drug release profiles.

[0008] The applicant's previous work outlined in WO2016 / 038356 (University of Central Lancashire), which focused primarily on the use of FDM filaments containing drugs in 3D printing, aims to address one or more of the above-mentioned problems. However, there remains a need for alternative solutions. Although WO2016 / 038356 provides various innovative options for reducing the melting / softening temperature of drug-containing filaments, for some drugs (especially those with low decomposition temperatures), the filament printing temperature may still be too high and decomposition may occur during printing. In addition, the technology described in WO2016 / 038356 deploys a significant proportion of thermoplastics in the formation of the dosage form, which may be undesirable and limits the maximum drug loading. It is desirable to expand the scope of applicability of the 3D printing technology described in WO2016 / 038356, for example by allowing a wider range of input materials. For example, 3D printing of solid dosage forms containing peptides, proteins and other biological drugs is considered desirable, although these inherit stability challenges. Furthermore, it would be desirable to be able to provide such solid dosage forms having immediate release, enteric release and / or extended release properties.

[0009] It is therefore an object of the present invention to provide an improved process and / or an alternative process for producing a solid dosage form and to adequately address at least one of the problems inherent in the prior art. SUMMARY OF THE INVENTION

[0011] According to a first aspect of the present invention, there is provided an apparatus for preparing (or printing) a solid dosage form, the apparatus comprising:

[0012] 3D printers; and

[0013] a build platform on which the solid dosage form is printable (i.e., the solid dosage form can be built on the build platform); and

[0014] a computer for controlling the 3D printer and optionally also the build platform;

[0015] Wherein the device (or 3D printer) comprises or is otherwise associated with:

[0016] a structure printing nozzle for printing a predefined three-dimensional shell comprising a shell composition onto a build platform; and

[0017] A non-structured dispenser for non-structured dispensing of the core composition (which is suitably a liquid and / or a particulate solid) into the shell.

[0018] (Wherein the FFF 3D printer is suitably operable via a computer to print a solid dosage form on a build platform, the computer being suitably a computer running according to specialized solid dosage form printing software and optionally also running according to one or more databases. Any one or more of the build platform, core composition, shell composition, and / or computer, and / or any part thereof may suitably be integrated within or form part of a FFF 3D printer.)

[0019] According to a further aspect of the present invention, there is provided a method for preparing (or printing) a solid dosage form, the method comprising:

[0020] printing a predefined three-dimensional open shell comprising a shell composition (or a precursor thereof) onto a build platform;

[0021] dispensing the core composition (or a precursor thereof) into the open shell to produce an open core-containing shell;

[0022] The open core-containing shell is closed by printing a closure on the open core-containing shell, the closure optionally comprising the shell composition (or a precursor thereof).

[0023] According to a further aspect of the invention there is provided a computer for operating an apparatus for preparing (or printing) a solid dosage form as defined herein, wherein the computer comprises:

[0024] an interface connecting or enabling the computer to connect (whether wirelessly or by wire) to or within a solid dosage form printing apparatus (suitably to allow the computer to control and / or operate said solid dosage form printing apparatus);

[0025] wherein the computer operates in accordance with solid dosage form printing software (and optionally also in accordance with one or more databases), the solid dosage form printing software configuring the computer to perform the following steps:

[0026] i) obtaining information (e.g., by manual user input or via one or more databases, optionally in response to a user-entered reference, such as a patient's name) about one or more parameters relating to the solid dosage form to be printed (e.g., active ingredient, active loading / dose, shape, release profile, etc.);

[0027] ii) calculating the mass and / or volume of the solid dosage form to be printed based on the information obtained in step (i);

[0028] iii) based on the information obtained in step (i) and the calculations performed in step (ii), controlling the printing and relative proportions of the ingredients within (i.e., constituting) the solid dosage form by:

[0029] a. controlling the printing, deposition and / or extrusion of the shell composition (or its precursor, whether its chemical transformation occurs after printing, deposition and / or extrusion) and the core composition (or its precursor, whether its chemical transformation occurs after printing, deposition and / or extrusion);

[0030] b. optionally controlling the printing, deposition and / or extrusion of one or more additional printing compositions;

[0031] c. Optionally controlling the performance of one or more additional processing steps.

[0032] According to a further aspect of the invention, there is provided a computer-implemented method of operating an apparatus for preparing (or printing) a solid dosage form, or a computer-implemented method of preparing (or printing) a solid dosage form, the method comprising:

[0033] A computer (having a suitable data connection to the relevant printing device, whether they are wired or wireless) operating in accordance with the solid dosage form printing software (and optionally also in accordance with one or more databases) is operated to:

[0034] i) obtaining information (e.g., by manual user input or via one or more databases, optionally in response to a user-entered reference, such as a patient's name) about one or more parameters related to the solid dosage form to be printed (e.g., active ingredient, active loading / dose, shape, release profile, shape, color, etc.);

[0035] ii) calculating the mass and / or volume of the solid dosage form to be printed based on the information obtained in step (i);

[0036] iii) based on the information obtained in step (i) and the calculations performed in step (ii), controlling the printing and relative proportions of the ingredients within (i.e., constituting) the solid dosage form by:

[0037] a. controlling the printing, deposition and / or extrusion of the shell composition (or its precursor, whether its chemical transformation occurs after printing, deposition and / or extrusion) and the core composition (or its precursor, whether its chemical transformation occurs after printing, deposition and / or extrusion);

[0038] b. optionally controlling the printing, deposition and / or extrusion of one or more additional printing compositions;

[0039] c. Optionally controlling the performance of one or more additional processing steps.

[0040] According to a further aspect of the invention, there is provided a computer program comprising solid dosage form printing software code for performing the computer implemented method defined herein when the computer program is run on a computer.

[0041] According to a further aspect of the invention, there is provided a blueprint (or computer readable code) for preparing (or printing) a solid dosage form as defined herein, the blueprint comprising information about one or more parameters related to the solid dosage form to be printed (e.g. active ingredient, active loading / dose, shape, release profile, shape, color, etc.).

[0042] According to a further aspect of the invention, there is provided a computer readable medium comprising solid dosage form printing software code executable to cause a computer to perform a computer-implemented method as defined herein when said software code is executed on the computer.

[0043] According to a further aspect of the invention there is provided a computer readable medium comprising a blueprint for preparing (or printing) a solid dosage form as defined herein.

[0044] According to a further aspect of the invention, there is provided a solid dosage form obtainable, obtained or directly obtained by a method of preparing (or printing) a solid dosage form as defined herein.

[0045] According to a further aspect of the present invention, there is provided a solid dosage form comprising a core and a three-dimensional shell surrounding the core;

[0046] in:

[0047] The shell comprises a shell composition, which suitably comprises (or is formed from) a 3D printing composition (e.g. a fused filament fabrication composition), wherein the shell composition is suitably (structurally) solid; and

[0048] The core comprises a core composition comprising an active ingredient, suitably a pharmaceutically active ingredient, a nutritionally active ingredient or a food supplement active ingredient, wherein the core composition (suitably a solid, liquid or gel) is suitably contained by the shell.

[0049] According to a further aspect of the invention there is provided a method of producing a solid dosage form package, the method comprising packaging one or more solid dosage forms as defined herein, wherein the one or more solid dosage forms are optionally the same or different.

[0050] According to a further aspect of the present invention, there is provided a solid dosage form package obtainable, obtained or directly obtained by the method of producing a solid dosage form package as defined herein.

[0051] According to a further aspect of the invention there is provided a solid dosage form package comprising within the package one or more solid dosage forms as defined herein.

[0052] According to a further aspect of the invention there is provided a kit of parts comprising a shell composition (suitably as defined herein) and a core composition (suitably as defined herein).

[0053] The method of using the device and judicious variations thereof may be applied (as appropriate) to any of the devices defined herein.

[0054] Any features (including optional, suitable and preferred features) described in relation to any particular aspect of the invention may also be features (including optional, suitable and preferred features) of any other aspect of the invention. BRIEF DESCRIPTION OF THE DRAWINGS

[0056] In order to better understand the present invention and to show how embodiments of the present invention may be put into practice, reference is now made by way of example to the following schematic diagram, in which:

[0057] Figure 1 is a schematic diagram of a dual FDM 3D printer adapted to accommodate either a) a liquid dispenser or b) a powder / granule / pellet dispenser in conjunction with an FDM 3D printer head.

[0058] Figure 2 A dual FDM 3D printer adapted to accommodate a liquid dispenser in conjunction with an FDM 3D printer head is shown and is further illustrated by arrows connecting images of a basic core-shell structure and the associated prints, the component being configured to print each portion of the core-shell structure.

[0059] Figure 3 Shown is a portion of a dual FDM 3D printer adapted to accommodate a liquid dispenser (right) in conjunction with an FDM 3D printer head (left).

[0060] Figure 4 is a graph showing the time course in vitro drug release profile of dipyridamole release from Eudragit L based capsules filled with drug suspension.

[0061] Figure 5 Calibration curves showing actual volume versus theoretical volume printed using a single head with a nozzle size of (a) 0.25 mm, (b) 0.41 mm, or (c) 0.84 mm.

[0062] Figure 6 Calibration curves of actual volume versus theoretical volume are shown for dual print heads using (a) 0.25 mm, (b) 0.41 mm, or (c) 0.84 mm nozzle sizes.

[0063] Figure 7 The relationship between the actual volumes of single and double prints from (a) 0.25 mm, (b) 0.41 mm, or (c) 0.84 mm nozzles is shown.

[0064] Figure 8 Shown is the in vitro release of dipyridamole from Eudragit L based capsules filled with different loadings of the drug suspension.

[0065] Fig. 9 The release profile of dipyridamole from the immediate-release shell is shown.

[0066] Fig.10 Renderings and photographs of liquid capsules made of immediate release shells (Eudragit E shells) and filled with a microsuspension of dipyridamole (1.5% w / v) are shown.

[0067] Fig.11 is a graph showing the effect of single and alternating printing modes from a liquid dispenser using a 2 mL syringe.

[0068] Fig.12 is a graph showing the effect of single and alternating printing modes from a liquid dispenser using a 10 mL syringe.

[0069] Fig.13 is a graph showing the linear relationship between a theoretical volume calculation based on a designed volume and an actual dose obtained via 3D printing.

[0070] Fig.14 Shown is the in vitro immediate release profile of dipyridamole suspension from 3D printed liquid Eudragit EPO capsules in gastric medium (pH 1.2) using USPII at different core volumes.

[0071] Fig.15 Shown are SEM images of the top of shells produced by two different filling patterns: a) concentric filling and b) rectangular filling.

[0072] Fig.16 The release profile of theophylline-core-capsules produced with immediate release shells containing Eudragit EPO is shown.

[0073] Fig.17The release profile of theophylline-core-capsules produced with extended release shells containing Eudragit RL 100 is shown.

[0074] Fig.18 A calibration curve for a powder dispenser (pinch valve) is shown.

[0075] Fig.19 Theophylline particles are shown in Immediate Release In vitro dissolution profile of 3D printed capsules in USPII dissolution test in gastric medium (0.1 M HCl).

[0076] Fig. 20 Shows 3D printed filled with theophylline particles Delayed release In vitro dissolution profile of enteric-coated capsules in gastric medium (0.1 M HCl). DETAILED DESCRIPTION OF THE INVENTION

[0078] definition

[0079] Unless otherwise stated, the following terms used in the specification and claims have the following meanings set forth below.

[0080] Throughout the description and claims of this specification, the words "comprise" and "contain" and their variations mean "including but not limited to", and they are not intended to (and do not) exclude other parts, additives, components, integers or steps. In the description and claims of this specification, the singular encompasses the plural unless the context requires otherwise. In particular, where the indefinite article is used, this specification should be understood to contemplate the plurality as well as the singular, unless the context requires otherwise.

[0081] Features, integers, characteristics, compounds, chemical moieties or groups described in conjunction with a particular aspect, embodiment or example of the invention are to be understood to be applicable to any other aspect, embodiment or example described herein unless incompatible therewith. All features disclosed in this specification (including any attached claims, abstracts and drawings) and / or all steps of any method or process so disclosed may be combined in any combination, except combinations in which at least some of such features and / or steps are mutually exclusive. The invention is not limited to the details of any foregoing embodiments. The invention extends to any novel feature or any novel combination of features disclosed in this specification (including any attached claims, abstracts and drawings), or to any novel step or any novel combination of steps in the steps of any method or process so disclosed.

[0082] The reader's attention is directed to all papers and documents filed concurrently with or before this specification in connection with this application and which are open to public inspection with the present specification, and the contents of all such papers and documents are hereby incorporated by reference.

[0083] For the avoidance of doubt it is hereby stated that the information disclosed earlier in this specification under the heading "Background" is relevant to the present invention and is considered to be part of the disclosure content of the present invention.

[0084] Unless otherwise stated, any reference to the term "melt" (or its derivatives) herein, particularly in the context of melting filaments, suitably includes the glass transition or softening of a given material, suitably to allow its extrusion (e.g. through a nozzle). However, in the context of a defined "melting point" of a substance, the term "melt" is as defined in the art - a phase change from solid to liquid.

[0085] In this document, references to the glass transition temperature or T g Suitably, the glass transition temperature (Tg) of the materials described herein may be determined by standard test methods, suitably using dynamic mechanical analysis - suitable tests include the test protocol defined by ASTM E1640. Differential Scanning Calorimetry (DSC) may also be used. For example, the glass transition temperature may be discerned using the protocols set forth in ASTM E1356 and ASTM D7426. Those skilled in the art will appreciate that references herein to the glass transition temperature of a particular material falling within a certain temperature range are intended to mean that at least one glass transition temperature of the material (which may or may not have multiple glass transition temperatures) falls within the temperature range. Suitably, unqualified references to "glass transition temperature" are intended to mean that at least one glass transition temperature of the material (which may or may not have multiple glass transition temperatures) falls within the temperature range. Reference) refers to at least one glass transition temperature, suitably means the lowest glass transition temperature, and may suitably mean the glass transition temperature that absorbs the most thermal energy (or is the most endothermic). It is self-evident to the skilled person that sufficient softening of the material occurs under specific environmental circumstances (e.g. at the printing nozzle, where the filament needs to be softened in order to be extruded during the printing process, and can then be re-solidified or re-hardened).

[0086] Unless otherwise specified, the term "viscosity" as used herein refers to the viscosity of the <912> Method II defines the test protocol, viscosity determined by Brookfield viscometer (UL adapter / 30 rpm / 20°C).

[0087] Unless otherwise stated, any reference herein to an "average" value is intended to relate to the mean value.

[0088] Where a composition is said to comprise a plurality of specified ingredients (optionally in specified amounts of concentration), the composition may optionally include additional ingredients in addition to those specified. However, in certain embodiments, a composition that is said to comprise a plurality of specified ingredients may actually consist essentially of or consist of all of the specified ingredients.

[0089] In this article, where a composition is said to "consist essentially of a particular component", the composition suitably comprises at least 70 wt% of the component, suitably at least 90 wt% of the component, suitably at least 95 wt% of the component, most suitably at least 99 wt% of the component. Suitably, a composition said to "consist essentially of a particular component" consists of the component except for one or more trace impurities.

[0090] In the case where the amount or concentration of a particular component of a given composition is specified as a weight percentage (wt% or %w / w), the weight percentage refers to the percentage by weight of the component relative to the total weight of the composition as a whole. It will be appreciated by those skilled in the art that the sum of the weight percentages of all components of a composition will add up to 100wt%. However, in the case where not all components are listed (e.g., where a composition is said to "comprise" one or more particular components), the weight percentage surplus may optionally be supplemented to 100wt% by unspecified ingredients (e.g., diluents, such as water, or other non-essential but suitable additives).

[0091] In this document, unless otherwise specified, when used in relation to a plurality of ingredients / components, the term "part" (e.g., part by weight, pbw) refers to the relative ratios between the plurality of ingredients / components. The molar ratios or weight ratios expressing two, three or more components produce the same effect (e.g., the molar ratios of x, y and z are x1:y1:z1, respectively, or the range of x1-x2:y1-y2:z1-z2). Although in many embodiments, the amount of a single component in a composition may be given as a "wt%" value, in an alternative embodiment, any or all of such wt% values ​​may be converted to parts by weight (or relative ratios) to define a multi-component composition. This is because in the liquid pharmaceutical composition of the present invention, the relative ratios between the components are generally more important than their absolute concentrations. In the case where a composition comprising a plurality of ingredients is described only in terms of parts by weight (i.e., only the relative ratios of the ingredients are indicated), it is not necessary to specify the absolute amounts or concentrations of the ingredients (whether in general or individually), because the advantages of the present invention may be derived from the relative ratios of the ingredients rather than their absolute amounts or concentrations. However, in certain embodiments, such compositions consist essentially of or consist of the specified ingredients and a diluent (eg, water).

[0092] The term "molar percent" (i.e., mol%) is well understood by those skilled in the art, and the mol% of a particular constituent means the amount of the particular constituent (expressed in moles) divided by the total amount of all constituents (including the particular constituent) converted to a percentage (i.e., by multiplying by 100). The concept of mol% is directly related to the molar fraction.

[0093] The term "substantially free", when used with respect to a given component of a composition (e.g., "a liquid pharmaceutical composition substantially free of Compound X"), refers to a composition into which substantially no such component has been added. When a composition is "substantially free" of a given component, the composition suitably contains no more than 0.001 wt% of the component, suitably no more than 0.0001 wt% of the component, suitably no more than 0.00001 wt% of the component, suitably no more than 0.000001 wt% of the component, suitably no more than 0.000001 wt% of the component, and most suitably no more than 0.0001 parts per billion (by weight).

[0094] The term "entirely free," when used with reference to a given component of a composition (eg, "a liquid pharmaceutical composition entirely free of Compound X"), refers to a composition that does not contain that component.

[0095] Suitably, unless otherwise stated, where reference is made to a parameter (e.g. pH, pKa, etc.) or state of a material (e.g. liquid, gas, etc.) that may depend on pressure and / or temperature, suitably in the absence of further clarification, such reference refers to said parameter at standard ambient temperature and pressure (SATP). SATP is a temperature of 298.15K (25°C, 77°F) and an absolute pressure of 100kPa (14.504psi, 0.987 atm).

[0096] In this article, the term "particle size" or "pore size" refers to the length of the longest dimension of a given particle or hole, respectively. Particle size and pore size can be measured using methods well known in the art, including laser particle size analyzers and / or electron microscopes (e.g., transmission electron microscopes TEM or scanning electron microscopes SEM).

[0097] General points and advantages associated with the present invention

[0098] The present invention deploys 3D printing technology to produce solid dosage forms, particularly pharmaceutical dosage forms, but those skilled in the art will readily appreciate that the principles of the present invention can be readily applied to nutraceuticals and food supplements. The 3D printing apparatus of the present invention uniquely juxtaposes standard 3D printing components with one or more non-printing dispensers so that they are together operable to print a solid 3D shell that encapsulates a core composition that has been dispensed into the shell in a non-printing manner. The standard 3D printing components may include a printing nozzle, preferably at least one non-powder-based printing nozzle, such as a printing nozzle for fused filament fabrication (FFF) printing, together with any associated conveying and / or heating equipment that allows the printed composition to be printed onto a surface, typically in a sequential layered manner. The non-printing dispenser may include any dispensing device that allows liquids and / or solids to be dispensed therefrom (suitably in a bulk manner as opposed to a sequential layered manner) into a safe container (containment vessel) of a solid dosage form size. For example, this can include syringes (which can dispense liquids, emulsions, dispersions, suspensions, nanosuspensions, or even powdered solids), valve-operated and optionally pressurized hoppers (which can dispense solids or liquids), and the like. Importantly, the 3D shell is printed (often discernible by the printed layered structure), while the inner core is not printed (and is instead a bulk dispensed material with no discernible layered structure).

[0099] Suitably, concentric packing may be used to form the shell.

[0100] In general, the printing of the solid dosage form of the present invention can be achieved by initially printing the partial shell before dispensing the core composition (usually a free-flowing liquid, solid or suspension) into the partial shell before finally closing the partial shell by printing a closure on the partial shell to completely encapsulate the core composition therein. In this way, the partial shell can be used as a transient but structurally stable open container for the core composition before the partial shell is finally closed to allow the solid dosage form to be further manipulated and packaged without leaking the core composition. The encapsulating shell is also suitably used to maintain the chemical integrity of the core composition therein.

[0101] The method of the present invention, particularly where the standard 3D part includes at least one non-powder based printing nozzle, overcomes many of the shortcomings of prior art powder based 3D printing techniques. For example, the present invention allows for the formation of a strong, well defined, high resolution shell structure that can provide a secure solid container for the powder (or indeed liquid) therein. Such an approach avoids the need for long drying times, which are characteristic of inefficient powder based printing processes.

[0102] Those skilled in the art will appreciate that various well-known methods of 3D printing may be deployed to form a solid shell, and indeed a mixture of such methods may be used where appropriate or beneficial. Although the present disclosure focuses on efficient and low-cost FFF / FDM methods of 3D printing (i.e., with filaments), the underlying principles of the invention are more broadly applicable.

[0103] In addition, the method of the present invention overcomes many disadvantages associated with FFF-based printing of solid dosage forms. For example, the present invention allows the benefits of FFF printing to be enjoyed in the printing of 3D shell structures, while alleviating its disadvantages by dispensing potentially heat-sensitive core materials in a manner that does not require heating or dilution of the applied active (e.g., in FFF filaments). Therefore, high loadings of thermosensitive active ingredients can be achieved in the solid dosage forms of the present invention. This also reveals the advantages of 3D printing technology in the field of biopharmaceuticals, such as the field of antibodies, polypeptides, glycopeptides, and analogs.

[0104] Thus, the solid dosage forms of the present invention can be produced "on demand" and adapted to the needs of a specific patient in a personalized and customized manner, thereby avoiding certain undesirable medical compromises (e.g., patients receiving an imperfect dose due to the limited range of sizes of mass-produced dosage forms provided). Separating the active ingredient from the 3D structure-forming material allows dosage forms to be made in a range of shapes and sizes because fewer constraints are imposed during the 3D structure formation event (e.g., constraints otherwise imposed by the presence of heat-sensitive active ingredients).

[0105] The present invention expands the applicability of 3D printing to a wider range of physical forms, allowing active ingredients to reside in solid and / or liquid compositions appropriate to the active in question.

[0106] Although chemical and physical compatibility between the core and shell must be considered when developing a durable solid dosage form, separation of the processes for forming each provides a better opportunity to maximize such compatibility.

[0107] It is expected that the present invention will make a significant contribution to the art in the production, distribution and consumption of pharmaceutical products and that this will have a positive health impact on all concerned.

[0108] Solid dosage form printing equipment and related equipment and software

[0109] The present invention provides an apparatus for preparing (or printing) a solid dosage form, which is suitably as defined herein. Suitably, the apparatus is operable to form a solid dosage form (e.g., a capsule) via a combination of 3D printing (suitably layer by layer) (particularly producing a 3D shell) and a non-printing distribution of an active material (particularly producing a core within a 3D shell). Therefore, the apparatus suitably includes one or more printing nozzles for printing a 3D shell and one or more dispensers for distributing core ingredients. At least some of the 3D printing performed by the apparatus of the present invention or the 3D printing performed by the apparatus of the present invention suitably involves fused filament manufacturing (FFF) printing using a printing filament, the printing filament comprising a specific filament composition, typically comprising a thermoplastic. FFF printing is particularly preferred for forming a shell. Therefore, suitably, the apparatus employs pre-manufactured filaments, which are selectively extruded and deposited in a layer-by-layer printing process to produce a shell. The non-printing dispensing of active-containing material (e.g. within a core composition) or at least some of the non-printing dispensing of active-containing material suitably involves batch dispensing of flowable (e.g. fluid) material suitably in a metered (i.e. precisely dosed) manner. The apparatus may suitably include one or more conveyors to deliver the relevant material to a suitable nozzle or dispenser.

[0110] The apparatus suitably comprises a fused filament fabrication 3D printer (FFF 3D printer). Such printers are often referred to as fabrication deposition modelling TM (Manufacturing deposition molding TM )(FDM)3D printer.

[0111] The apparatus suitably comprises a build platform (or build plate) on which the solid dosage form is printable (i.e., the solid dosage form can be built). The build platform suitably provides a (substantially flat) surface that supports the solid dosage form throughout the printing process. In particular embodiments, the build platform comprises a surface, tape layer (i.e., a tape layer at the surface), or surface coating that promotes adhesion of the solid dosage form to the build platform (i.e., promotes adhesion of the first layer of the solid dosage form to be printed on the build plate, suitably after the first layer hardens upon cooling) during the printing process, although suitably the solid dosage form is (easily) removable from the build platform after its production.

[0112] Suitably, the device includes a computer interface (whether for wired or wireless connection to a computer operable to control the FFF 3D printer or printing device).

[0113] The apparatus suitably comprises a computer for controlling the FFF 3D printer. The computer may optionally control the build platform (e.g., its position, height, etc.).

[0114] Suitably, the apparatus comprises a structure printing nozzle for printing a predefined three-dimensional shell onto a build platform. Suitably, such a structure printing nozzle is characterized by an extrusion nozzle through which and from which a filament (or a portion thereof) can be extruded, suitably comprising a filament of a shell composition (suitably as defined herein) or a precursor thereof. Such a structure printing nozzle is suitably part of a 3D printer.

[0115] Suitably, the device includes a non-structural dispenser. The non-structural dispenser is suitably a vessel from which a core composition or its precursor can be dispensed. Contrary to the structured printing nozzle, the non-structural dispenser suitably dispenses the core composition (or its precursor) in an unstructured manner. Suitably, the non-structural dispenser is configured or otherwise operable to dispense the core composition (or its precursor) into a 3D shell printed via the structured printing nozzle. The non-structural dispenser can be a part of a 3D printer, or can be outside a 3D printer (e.g., at another station or module within the device as a whole).

[0116] The apparatus of the present invention may include one or more other components, optionally, a printing or dispensing component for printing or dispensing other materials intended to form a part of the solid dosage form. For example, the solid dosage form may include multiple shells. The solid dosage form may include a variety of different core compositions. The shell of the solid dosage form may include a compatibility layer on its inner surface, the compatibility layer comprising a substance or composition that increases the compatibility between the core and the shell or otherwise maintains the (substantial) separation between the core and the shell.

[0117] Structure Printing Nozzle

[0118] Suitably, the apparatus or 3D printer of the invention comprises one or more extrusion nozzles through and from which a filament (or a portion thereof) may be extruded, at least one of the one or more extrusion nozzles being a structure printing nozzle as defined herein. References herein to a nozzle and / or its characteristics, including optional characteristics thereof, suitably apply to the structure printing nozzle.

[0119] Suitably, the or each extrusion nozzle may be a heated extrusion nozzle, suitably a heated extrusion nozzle having a variable temperature control (e.g., to allow the extrusion nozzle to be selectively heated at a desired temperature). Thus, the apparatus may include an extrusion nozzle heating element, suitably for heating the extrusion nozzle to melt (or otherwise liquefy) the associated filament or a portion of the associated filament. Suitably, the apparatus may include a plurality of the extrusion nozzles described above, each of which may be assigned to one or more filaments. The printing apparatus may include one or more extrusion nozzle heating elements associated with the or each extrusion nozzle, suitably for heating the extrusion nozzle to melt (or otherwise liquefy) the associated filament or a portion of the associated filament. Suitably, the apparatus may include a plurality of the extrusion nozzles described above, each of which may be assigned to one or more filaments.

[0120] The temperature of the nozzle is suitably computer controlled.Suitably, the nozzle is configured to operate at a temperature between 60°C and 350°C, suitably between 80°C and 300°C, more suitably between 100°C and 220°C, suitably between 120°C and 190°C.

[0121] Suitably, each extrusion nozzle comprises an input opening (to which the filament is supplied) and an output opening (from which the molten filament is deposited). The output opening is suitably smaller than the input opening. The input opening is suitably sized to receive the corresponding filament passing therethrough. Suitably, the input opening has a diameter of 1.0 mm to 2.5 mm, more suitably 1.5 mm to 2.0 mm, most preferably about 1.75 mm. The output opening is suitably sized for the properties of the corresponding filament to allow the molten filament to be deposited therefrom (e.g., onto a build platform). Suitably, the output opening has a diameter of 50 μm to 400 μm, more suitably 100 μm to 300 μm, more suitably 150 μm to 250 μm, most suitably about 200 μm. In an embodiment, the nozzle has an output opening having a diameter between 200 μm and 500 μm.

[0122] Suitably, the or each nozzle may be movable (suitably in an automated manner or in a manner controlled by a computer or by a printer under instructions from a computer) to extrude the filament at different locations on the build platform (or on the partially formed solid dosage form printed thereon). The nozzle may be movable in any or all of the X, Y and Z directions, although in some embodiments (e.g. where the build platform is movable in the Z direction, i.e. up and down relative to the nozzle) it is constrained to movement in the X and Y directions only.

[0123] Suitably, the extrusion nozzle or each extrusion nozzle is operable to move at a speed of between 50 mm / s and 150 mm / s, more suitably between 70 mm / s and 110 mm / s, more suitably between 80 mm / s and 100 mm / s when extruding (i.e. when the nozzle is "on" - this may be the nozzle extrusion speed). Suitably, the extrusion nozzle or each extrusion nozzle is operable to move at a speed of between 100 mm / s and 200 mm / s, more suitably between 120 mm / s and 180 mm / s, more suitably between 140 mm / s and 160 mm / s when not extruding (i.e. when the nozzle is "off" - this may be the nozzle traveling speed).

[0124] Those skilled in the art will appreciate that the, each or any nozzle may be adapted to suit the properties of the corresponding filament it is configured to print onto. The nozzle properties / design and filament properties / composition suitably complement each other so as to facilitate controlled extrusion of the filament (whether continuous or intermittent, such as where more than one filament is used in the printing of a solid dosage form), suitably without any nozzle blockage or obstruction, and suitably without any unacceptable degradation of components within the filament during the printing process.

[0125] Suitably, the apparatus comprises a conveyor for conveying the printing filament and any optional one or more additional printing filaments to and / or through at least one extrusion nozzle. Suitably, the conveyor clamps the relevant filament and feeds the relevant filament toward and / or through the relevant extrusion nozzle by itself. Suitably, the conveyor is controlled so as to deliver the relevant filament at a rate and / or interval suitable for providing the desired solid dosage form. The conveyor or a portion thereof (e.g., a "feeder") (preferably a portion on the way to the extrusion nozzle) may be heated, suitably via a heating element associated therewith, optionally a separate and / or individually controllable heating element from any heating element associated with the extrusion nozzle. In the case where the apparatus comprises more than one nozzle, suitably the apparatus comprises more than one feeder, each feeder being associated with each extrusion nozzle.

[0126] Non-structural allocator

[0127] The apparatus of the invention suitably comprises one or more non-structured dispensers, most suitably one non-structured dispenser for each core composition processed by the apparatus.Suitably, the non-structured dispenser is operable to dispense a liquid (whether or not the liquid contains particulate matter) or a particulate solid.

[0128] According to aspects of the invention, there is provided a non-structural dispenser comprising a mounting element that allows the non-structural dispenser to be mounted in an apparatus as defined herein, or more suitably in a 3D printer as defined herein. In some embodiments, the non-structural dispenser may be or include a core dispensing cartridge that is suitably pre-loaded with a specific core composition (or a precursor thereof) intended for dispensing. Thus, the non-structural dispenser may suitably contain a core composition or a precursor thereof.

[0129] The or each non-structural dispenser suitably comprises a container, suitably a sealed or sealable container, and an outlet through which the core composition (or a precursor thereof) can be dispensed. Suitably, the outlet is characterized by a tubular structure (e.g. a needle, tube or conduit), suitably a substantially rigid tubular structure, suitably a tubular structure having a bore size that is smaller than the largest dimension of the solid dosage form to be produced - this allows for increased precision in dispensing.

[0130] The non-structural distributor may include a pressurizing element or may otherwise be connected to a pressurizing element. Such a pressurizing element (e.g., a syringe piston) may help distribute, particularly in a metered manner. Various pressurizing elements may be used, such as plungers / pistons, screw rods (e.g., Archimedean screws) and the like.

[0131] The non-structural dispenser, in particular its outlet, may include or otherwise be connectable to a valve, suitably a one-way valve, operable (suitably electronically, suitably under the control of a computer running according to suitable software) to open and close to allow the core composition in the dispenser to be selectively dispensed. In certain embodiments, such a valve may be deployed in conjunction with a pressurizing element. Suitably, both the valve and the pressurizing element may be computer operated to dispense a metered dose of the core composition (or its precursor) residing in the dispenser.

[0132] Suitably, the non-structural dispenser is operable to dispense single-dose or multi-dose core compositions (or its precursor) in a metered manner. Suitably, the non-structural dispenser includes a quantitative component or is otherwise associated with a quantitative component, which is used to measure the amount of the core composition (or precursor) to be dispensed. The distribution can be, for example, weight and / or volume. Suitably, the apparatus of the present invention can be operated under computer control to coordinate the metered distribution of the core composition (or its precursor) of each dose with the printing of the shell. Therefore, the structural printing nozzle and the non-structural dispenser suitably work in a coordinated and complementary manner under the control of the same computer and / or computer program. However, in some embodiments, the apparatus of the present invention can be envisioned to include multiple workstations, including, for example: a partial shell printing station, a core distribution station, and a shell closure station. In such an embodiment, before being transported to the core distribution station, multiple partial shells can be printed, at which point the partial shells are "filled" with core compositions (or their precursors). Thereafter, the plurality of "filled" partial shells may be conveyed to a closing station which completes the solid dosage form, or at least completes the core-shell arrangement which may then undergo further processing.

[0133] Suitably, the non-structured dispenser is not heated or otherwise associated with a temperature control element that maintains the non-structured dispenser (and suitably also its contents) at a temperature of 90°C or below, suitably at a temperature of 60°C or below, suitably at a temperature of 50°C or below, suitably at a temperature of 40°C or below, more suitably at a temperature of 30°C or below, suitably at a temperature of 0°C or above, suitably at a temperature of 10°C or above. Such a temperature control element may be a thermocouple.

[0134] The non-structural dispenser may include insulation, such as an outer insulating layer, to protect the non-structural dispenser and / or its contents from overheating caused by adjacent components during operation of the apparatus of the present invention.

[0135] Suitable internal coatings may be deployed at the outlet of a dispenser to alleviate clogging, whether the dispenser is designed to dispense solids, liquids, or liquid suspensions.

[0136] The non-structural dispenser may be operable to dispense solids, particularly granular solids such as powders.

[0137] Non-structured dispensers may be operable to dispense liquids, particularly solutions, but also dispersions (eg, colloidal dispersions), emulsions, and even suspensions (eg, nanosuspensions).

[0138] In some embodiments, the non-structural dispenser can distribute a liquid core composition precursor, which eventually forms a solid or gelled core composition in a solid dosage form. Equally, the non-structural dispenser can distribute a solid core composition precursor, which eventually forms a liquid or gelled core composition in a solid dosage form. In such an embodiment, the core composition precursor is suitably subjected to chemical and / or physical transformation after distribution (or even during distribution). Such a transformation can cause in a variety of ways, and the method for using this device will be discussed below in conjunction with it.

[0139] In some embodiments, the non-structured dispenser includes one or more additional dispensers, or is otherwise associated with one or more additional dispensers, which can be suitably operated in conjunction with the aforementioned non-structured dispenser to cause the core composition precursor to mix with one or more core reactants or additional core composition precursors during its dispensing or after its dispensing period. For example, one or more core composition precursors and / or reactants can be pre-mixed in a mixing chamber during their dispensing, or one or more composition precursors and / or reactants can be sequentially dispensed into the same target (i.e., dispensed into the same partial shell).

[0140] Solid non-structural distributor

[0141] The non-structural distributor can be any suitable solid dispensing device or otherwise include any suitable solid dispensing device. Various solid dispensing devices are known in the art. The core composition (or its precursor) for dispensing by the device of the present invention can be in the form of powder, granules or pellets.

[0142] Suitably, the solid non-structured dispenser is a granular solid dispenser, such as a powder dispenser, suitably an automated powder dispenser.

[0143] Suitably, the solid non-structured dispenser is operable to dispense solids, suitably granular solids, such as powders and granules, in a metered (i.e., metered-dose) manner. Such a dispenser may be integrated with the apparatus of the present invention, and in some embodiments, part or all of the non-structured dispenser may be incorporated into the 3D printer itself. Various prior arts may be feasibly integrated in this manner. For example, BioDot TM ( www.biodot.com )'s DisPo TM Powder dispensing technology enables metered dispensing of solids / powders in single doses ranging from 100 μg to 20 mg.Such a dispenser comprises a sampling chamber for sampling a metered dose (eg core composition) and a sample ejection system for dispensing the sampled solid.

[0144] The solid non-structural distributor suitably includes a primary storage container, such as a hopper. The primary storage container suitably contains a solid (suitably a particle) core composition or a precursor thereof. The primary storage container is suitably sealed. The primary storage container can be in the form of a box specifically adapted to be compatible with the apparatus of the present invention. The primary storage container suitably has: an outlet (such as a valve-operated tap, optionally combined with a positive dispensing device such as a pressurizer or agitator), through which and from which its contents can be dispensed; or a sampling port, from which contents can be extracted by an external sampling element.

[0145] The solid non-structured dispenser suitably comprises one or more dispensing containers. Suitably, such dispensing containers are configured to suitably receive a certain amount of the core composition (or its precursor) from the main storage container directly or via a delivery device. Suitably, one or more dispensing containers can receive a predetermined dose of the core composition (or its precursor).

[0146] Solid non-structured dispenser compatibly comprises quantitative components, for example weight or volume components.Such quantitative components compatibly weigh or otherwise quantitatively treat the solid of each dosage to be distributed.Suitably, non-structured dispenser is operable to be delivered to quantitative components or delivered to the distribution container interacting with quantitative components by a certain amount of core composition (or its precursor) from main storage container.Suitably, one or more distribution containers are positioned so that quantitative components can quantitatively be received by the distribution container The amount of the core composition.Selectively, quantitative components can be associated with main storage container, and thereby measure the quality reduction when solid is distributed from main storage container.Quantitatively can be carried out by weight and / or by volume.

[0147] The solid non-structural dispenser suitably includes a flow control component that suitably controls and meters the distribution of the core composition (or its precursor) from the main storage container to one or more distribution containers. The flow control component may, for example, include a controlled feed mechanism, and may suitably include an Archimedean screw, a valve, an agitator (e.g., for vibration, knocking, or shaking). Alternatively or additionally, the flow control component may include a sampling probe that is operable to sample (estimate) a certain amount of solid from the main storage container-the sampling probe may be suitable for dispensing the solid directly into the (partially formed) solid dosage form, although preferably, the sampling probe will first dispense the solid into the distribution container in order to accurately verify the amount of the solid to be ultimately dispensed.

[0148] The solid non-structural dispenser suitably includes an expulsion mechanism for expelling a quantitative amount of the core composition (or its precursor) from the sampling probe or the dispensing container. Such an expulsion mechanism may suitably include a release device (e.g., a tap, a valve, a vacuum release mechanism or other such mechanism, which can, for example, pour the contents from the dispensing container toward the target dispensing point). Alternatively or additionally, the expulsion mechanism may include an expulsion means, such as a pressurizer, a stirrer, a screw, a piston or a plunger, which forces the core composition (or its precursor) to be discharged from the dispensing container, thereby dispensing the solid.

[0149] In one embodiment, the solid non-structural dispenser includes a hopper and a movable metering element (e.g., a shuttle plate) that is movable relative to the hopper and includes a metering cavity / container of fixed or adjustable size. The size of the metering cavity determines the size of each dose. The movable metering element may be operable to receive a certain amount of solid from the hopper before enclosing the metered amount of solid in the cavity, moving to the dispensing point, and dispensing the solid from the metering cavity.

[0150] Those skilled in the art will be aware of certain challenges faced in metered dispensing of solids, particularly granular solids. Forces that favor outflow (e.g., gravity, pressure, and / or helical forces (e.g., forces of an Archimedean screw)) are often counteracted by forces acting against flow—e.g., interparticle adhesion, adhesion to parts of the dispenser (e.g., walls of the dispenser and / or dispensing outlet), wear, friction, unstable flow (e.g., ratholes or arched profiles during funnelling), compressibility (incompressible solids flow better), outlet restriction (e.g., orifice of the outlet), angle of repose during funnelling (angles less than or equal to 35° are preferred), external pressure (external vacuum can assist), etc. Outflow of particles is particularly affected by the particles themselves in terms of particle shape, particle size, particle density, particle chemical properties, surface roughness, and moisture content. Particle flow can be improved by judicious particle engineering, including techniques such as particle enlargement (e.g., granulation), cohesion reduction, smoothing / rounding, optimization of moisture content, co-grinding (e.g., to form a flow-enhancing nanocoating), and similar techniques. A compressibility index of less than or equal to 25%, preferably less than or equal to 15%, preferably 10% is reliable for better particle flow. In addition, particle sizes greater than or equal to 10 μm, suitably greater than or equal to 50 μm, suitably greater than or equal to 100 μm are generally preferred for optimal particle flow. Therefore, small particle sizes, including nanoparticles (e.g., less than or equal to 100 nm), can be better distributed in the form of suspensions, such as nanosuspensions.

[0151] Suitably, components of the solid non-structured dispenser are computer controlled and suitably any valves or pressurizers are electronically controlled.

[0152] In some embodiments, the solid non-structured dispenser may simply include a hopper with an outlet valve that is operable (preferably under computer control) to dispense a metered amount of the particle core composition (or its precursor) directly from the hopper into a partial shell of the solid dosage form. The dispensing of the granular solid may be entirely gravity, or may be facilitated by applying additional pressure to the hopper or within the outlet.

[0153] Suitably, a clench valve may be incorporated into the solid non-structural dispenser to control the dispensing flow of particulates, such as granules.

[0154] Liquid non-structural distributor

[0155] Liquid dispensers (which suitably include suspension, dispersion and emulsion dispensers) are generally simpler than solid dispensers as they present fewer challenges.

[0156] The non-structural dispenser can be any suitable liquid dispensing device or otherwise include any suitable liquid dispensing device. Various liquid dispensing devices are known in the art. The core composition (or its precursor) for dispensing by the device of the present invention can be in the form of a liquid such as a solution, dispersion, emulsion or suspension.

[0157] Suitably, the liquid non-structured dispenser is an automatic liquid dispenser.

[0158] Suitably, the liquid non-structural distributor is operable to distribute liquid in a metered (i.e., metered-dose) mode. Such a distributor can be integrated with the equipment of the present invention, and in some embodiments, a part or all of the non-structural distributor can be incorporated into the 3D printer itself. Various prior arts can be integrated in this way. For example, the distributor can include a syringe driver (or a syringe pump), suitably an automatic syringe driver. Suitably, the liquid non-structural distributor can be operated under computer control to distribute the liquid of the metered dose to each solid dosage form (or each partially formed dosage form). Suitably, the equipment of the present invention can be operated under computer control to coordinate the metered distribution of the core composition (or its precursor) of each dose with the shell manufacturing process.

[0159] Although as with solids, metered dispensing of liquids can be done in a variety of ways, including both gravimetrically and volumetrically, preferably liquids are dispensed volumetrically.

[0160] As with solid non-structural dispensers, the dispenser may include a primary storage container. However, in the case of liquids, the primary storage container may be directly fluidly connected to the final dispensing outlet according to the syringe, since accurate dispensing of the liquid is possible by volumetric dispensing without the need for subsequent quantitative checks.

[0161] As with solid distribution, the liquid non-structural distributor may include an outlet and optionally a pressurizing device. Therefore, the liquid may be distributed under gravity, vacuum or the like, and / or may be distributed under pressure, for example, from a piston / plunger. Suitably, the components of the liquid non-structural distributor are computer controlled, and suitably, any valve or pressurizer is electronically controlled.

[0162] Build the platform

[0163] The printing apparatus or 3D printer suitably comprises a build platform. This provides a platform on which the solid dosage form (particularly the shell and part of the shell) can be printed.

[0164] Suitably, during printing (e.g. at the relevant printing operating temperature), the surface of the building platform onto which the solid dosage form is to be printed adheres to the solid dosage form (or at least to the layer thereof in contact with the building platform) sufficiently to prevent movement of the developing solid dosage form during printing. However, suitably, after printing (e.g., optionally at a temperature different from the printing operating temperature), the printed solid dosage form can be removed from the building platform without being damaged (e.g., the building platform is non-adhesive enough to allow the solid dosage form to be removed or is selectively adjustable, such as by changing the operating temperature, to allow the solid dosage form to be removed therefrom). Thus, the surface of the building platform may include a surface coating or surface tape that imparts desired surface properties (e.g., sticky but not too sticky so that the solid dosage form is permanently adhered).

[0165] The build platform is suitably configured or operable to maintain a surface temperature (i.e., for the surface in contact with the solid dosage form) of less than or equal to 50°C, suitably less than or equal to 40°C, suitably less than or equal to 30°C, suitably greater than or equal to 5°C, suitably greater than or equal to 15°C during printing. In other embodiments, the build platform is operable to maintain a surface temperature of less than or equal to 150°C, suitably less than or equal to 100°C, suitably greater than or equal to 15°C. This may be achieved by selectively operating a heating and / or cooling element associated with a surface (e.g., underneath) of the build platform. In particular embodiments, the build platform is operable and preferably operated to maintain a surface temperature of between 20°C and 90°C, suitably between 20°C and 60°C, suitably between 30°C and 50°C, most suitably about 40°C.

[0166] The build platform may be movable (suitably in an automated manner or in a manner controlled by a computer or by a printer under instructions from a computer) to control the position or height of extrusion of the associated filament on the build platform. The build platform may be movable in any or all of the X, Y and Z directions, although in some embodiments the build platform is movable only in the Z direction, i.e., up and down. Movement in the Z direction allows the gap (or height) between the nozzle and the print point to remain substantially constant throughout the printing process to maintain layer-by-layer consistency.

[0167] 3D Printer

[0168] The 3D printer is suitably a FFF 3D printer. Conventional FFF 3D printers are well known in the art and are generally suitable for the present invention, although they can be judiciously modified based on the principles outlined herein to optimize the printing of solid dosage forms. For reference by technicians, the following research articles describe the feasible operation of FFF 3D printers—SH Masood, "Application of fused deposition modelling in controlled drug delivery devices", Assembly Automation, 27 / 3 (2007), pages 215-221 and Khaled et al., "Desktop 3D printing of controlled release pharmaceutical bilayer tablets", International Journal of Pharmaceutics, 461 (2014), pages 105-111—describe the use of FFF 3D printers to print into filaments, although there is no active ingredient contained in the filament being printed (the drug compound is injected at a later stage). In addition, PCT publication WO 2016 / 038356 of the present application also describes suitable equipment for use with the present invention, which application is hereby incorporated by reference.

[0169] FFF 3D printers suitable for use in the present invention typically include a heated / heatable extruder nozzle that melts and deposits (suitably deposited onto a build platform) molten filaments in a layer-by-layer manner. Suitably, the deposited molten filaments harden rapidly after deposition. Keeping the build platform with a relatively low surface temperature can contribute to such cooling / hardening to improve the final structure of the solid dosage form being printed. The FFF 3D printer also suitably includes one or more nozzle heaters (suitably nozzle heaters associated with each nozzle, but optionally nozzle heaters serving multiple nozzles) and suitably one or more conveyors as defined above (suitably conveyors associated with each filament and / or nozzle). Suitably, the FFF 3D printer includes one or more filament spool areas (or filament spool attachment points) for accommodating related filament spools.

[0170] The FFF 3D printer of the present invention may be adapted to incorporate one or more non-structural dispensers as defined herein. In this way, structural printing and non-structural dispensing may occur substantially simultaneously.

[0171] computer

[0172] The apparatus, including a 3D printer (and optionally a build platform), is suitably operable via a computer, suitably a computer running according to specialized solid dosage form printing software and optionally also according to one or more databases, to print a solid dosage form on the build platform, suitably via a process involving printing and / or extrusion of a shell-forming printing filament. The computer also suitably controls and coordinates the dispensing of the core composition (or its precursor), optionally simultaneously or sequentially with the printing of the shell.

[0173] Those skilled in the art will readily appreciate that any one or more of the build platform, printing filament, and / or computer, and / or any portion thereof may be suitably integrated within or form part of a 3D printer. In an embodiment, the printing device is substantially a 3D printer or printing device.

[0174] Suitably, printing device includes computer or is otherwise connected to computer. Suitably, printing device (or 3D printer) is connected to computer via interface (suitably digital interface), and the interface can be wired (for example, via port to port connection of suitable data lead (data lead), such as USB lead) or wireless. Computer can be located at the position (i.e. local computer) of relevant printing device or 3D printer. However, the present invention is equally applicable to the following situation: wherein relevant computer (or multiple computers) is located at the position away from relevant printing device or 3D printer, but printing device (or 3D printer) and remote computer both include corresponding communicator or are otherwise connected to corresponding communicator, and the communicator allows remote computer and printing device (or 3D printer) to communicate with each other. In this way, remote computer operation printing device can be caused. In a specific embodiment, printing device (or 3D printer) can be connected to a network so that multiple remote computers (and / or local computers) can communicate with it to cause the operation of printing device (or 3D printer).

[0175] A computer associated with or otherwise connected to the printing apparatus suitably controls the printing of the relevant filaments according to the solid dosage form design and / or solid dosage form parameters (e.g., relative amounts and juxtaposition of ingredients) set forth in a given solid dosage form data file (e.g., in a CAD or .STL file), suitably as interpreted by relevant software upon which the computer is run.

[0176] In certain embodiments, the printing device comprises or is connected to a local computer, and both the printing device and the local computer are located on-site at the pharmacy, most preferably in a dedicated printing area or room (which may suitably have regulatory approval).

[0177] Suitably, the method and / or apparatus involves a computer operating in accordance with solid dosage form printing software (and optionally one or more internal and / or external databases).

[0178] Suitably, the computer running in accordance with the solid dosage form printing software is configured to obtain information (e.g. whether from information manually input by a user or from information automatically obtained from another data source) about one or more parameters (optionally including physical design parameters such as shape) related to the solid dosage form to be printed. Suitably, the computer running in accordance with the solid dosage form printing software is configured to request manual user input via a user interface (e.g. keyboard / screen) about one or more parameters related to the solid dosage form to be printed. For example, a user (who may be a pharmacist acting under instructions from a patient and / or a physician) may be asked to enter information about a patient's name, a patient reference number (e.g., a health care number), and / or another reference name or number, whereupon the computer may (via an associated communicator associated therewith) communicate with one or more databases (whether local or remote, wired or wireless, e.g., via a network such as the Internet) to automatically call up additional information and / or options corresponding to the name or reference (e.g., personal patient data, medication history, repeat prescriptions, data or portions of data related to the solid dosage form to be printed, including a solid dosage form data file containing design and / or other relevant parameters). Thereafter, the user may be asked to manually enter or manually select additional information (e.g., medication, medication dosage, release profile, etc.) and / or options to allow the computer to obtain all relevant information related to the printing of the desired solid dosage form. Alternatively or additionally, the user may be required to manually input or call up information regarding one or more specific parameters associated with the solid dosage form (e.g., drug name / reference, drug dosage, drug release requirements, color, size, shape, solubility, package label information, etc.) Suitably, any user input may be recorded and / or stored for future reference or for repeat prescriptions, etc.

[0179] There are various ways in which the computer may be configured to obtain the relevant information to allow the solid dosage form to be printed, but it is possible that various preset information may be used (e.g. certain approved formulation / filament combinations for producing a given solid dosage form). Thus, the computer may suitably be associated with or connected / connectable to a solid dosage form database (suitably a central database accessible via a network such as the Internet) which provides all necessary preset information (e.g. data files relating to the solid dosage form and details of variable parameters such as drug dose levels / limits).

[0180] Suitably, the solid dosage form design for printing (and optionally parameters associated therewith) may be recorded in a solid dosage form data file which may be read by a computer operating in accordance with the solid dosage form printing software.

[0181] Suitably, the computer running according to the solid dosage form printing software is configured to calculate the mass and / or volume of the solid dosage form to be printed based on the information obtained. Suitably, after the computer has obtained all the required information (whether it is information manually input by the user, information automatically imported, or a combination of the two), the computer is configured to perform calculations to allow the printing instructions to be completed before the computer controls the printing. At this stage, additional input (e.g., via a user interface) may be required or requested, such as size and / or shape modification may be optionally selected. Calculations typically involve providing the mass and / or volume of a given solid dosage form required for a given active dose per dosage form. Although it can increase the concentration of a given active relative to other ingredients (e.g., excipients), typically the preparation is optimized and the relative proportion is fixed / preset, and the total mass / volume can vary while maintaining the relative proportion of the same ingredients.

[0182] Suitably, the computer operating in accordance with said solid dosage form printing software is configured to control the printing and relative proportions of the ingredients within the solid dosage form, suitably based on the information obtained and suitably based on the calculations performed. Suitably, "controlling printing" includes starting printing, terminating printing and any or all printing operations therebetween.

[0183] Suitably, during printing, operational data is collected (optionally by one or more local and / or remote computers and / or databases) and suitably stored (most preferably on a central computer where such data can be analysed, for example for quality control monitoring, fault monitoring, batch monitoring, monitoring of dosage forms allocated to a given patient, etc.). Suitably, the printing device comprises or is otherwise associated with one or more operational sensors (e.g. a nozzle temperature sensor, a filament feed rate sensor or conveyor sensor, an integral temperature sensor, a build platform sensor, which may for example monitor surface temperature and / or rate of post-print cooling, etc.), which feed back operational parameters / information to a computer, database or data storage facility relating to the operation of the printing device and elements associated therewith during the printing of each dosage form. Most preferably, such operational data is collected, stored and / or otherwise sent to a central computer or database to enable independent audit of any given printing device. This may be important in order to maintain quality control, and to keep appropriate records in order to maintain regulatory approval of any given 3D printing system.

[0184] Suitably, the computer operating in accordance with said solid dosage form printing software is configured to control the performance of one or more further processing steps.

[0185] Software and Data Files

[0186] The computer operating the printing device or 3D printer is suitably run according to the solid dosage form printing software (and optionally also according to one or more databases). As explained herein, the software can configure the computer to obtain information and perform calculations before it is configured to control printing via an interface with the printing device or 3D printer.

[0187] After the computer has obtained the relevant information and performed the relevant calculations, suitably, the software configures the computer to control the printing of the solid dosage form, suitably based on the design (shape and size, texture, layer structure, internal structure, porosity, color, etc.) and / or parameters related to the solid dosage form contained in one or more solid dosage form data files (relative amounts of ingredients, such as drug dosage). The solid dosage form data file may include a design file (e.g., containing data and / or images related to the physical design of the solid dosage form, including its size, shape, layered structure, core-shell structure, etc.) and / or a parameter file (e.g., containing data related to the chemical composition of the solid dosage form, including drug type, excipient type, drug dosage level, excipients for controlling drug release, etc.). A single solid dosage form data file may contain all data related to the physical design and chemical composition. However, the physical design and chemical composition may be modified according to the information obtained after user input.

[0188] In some embodiments, the design file can be a CAD file that depicts the solid dosage form. However, such a file format may need to be converted into a file format that is compatible with a printing device or 3D printer. Conventional 3D printers typically read design files in .STL format. Therefore, the design file is suitably a .STL design file that depicts the solid dosage form (or at least its physical design).

[0189] The design file may include a parameter file containing chemical composition details or be associated with a parameter file containing chemical composition details, or the two may be independent. Alternatively, there may be no such parameter file, but the relevant parameter information may be called from a database, for example in response to user input (e.g., patient reference or drug reference, etc.).

[0190] The software may additionally configure the computer to collect, store and / or send (e.g., to a central database) operational data fed back to the computer from the printing device or 3D printer during printing. The software may configure the computer to detect and / or respond to any (or preset levels of) deviations in expected operational data (e.g., if the nozzle temperature exceeds a maximum preset temperature level), for example alerting a user / operator or any other concerned party that a fault has occurred and that solid dosage forms produced during the faulty printing should be disposed of or otherwise tested.

[0191] database

[0192] The apparatus and / or a computer associated therewith may be configured (e.g. by solid dosage form printing software) to communicate with one or more solid dosage form databases and / or patient databases (suitably via an associated communicator, and suitably via a network such as the Internet) to obtain information about one or more parameters relating to the solid dosage form to be printed. For example, such a database may be queried in response to user input (e.g. a patient reference number) to provide the computer with relevant information (or relevant information to be supplemented by further user input) to enable calculation and printing to be performed.

[0193] By way of example, a patient database comprising patient records for a plurality of patients (which records may include, for example, patient names, patient reference numbers, medical data, medical history, etc.) suitably contains information about the solid dosage form to be printed for each patient (which may simply be a cross-reference or reference number to information present in another database, such as a solid dosage form database). Where the "information" is a cross-reference to a solid dosage form database, the solid dosage form database may then be queried for additional information about the solid dosage form. The information may be any information as defined herein, although optionally the printing device or a computer associated therewith may be instructed (e.g., via a user interface) to modify the information (e.g., drug dosage level) prior to calculation and / or printing. Any of these databases may be accessible to interested parties, preferably securely accessible (to maintain confidentiality of certain data), so that relevant information (whether in the patient database, the solid dosage form database, or both) can be retrieved and / or modified as required (e.g., if a patient requires an increased dose or a different active release profile in a printed solid dosage form). Suitably, such a database may be wirelessly accessible via a network such as the Internet. Such database architectures are well known in the art.

[0194] The or each printing device and / or a computer associated therewith may be configured (e.g. by solid dosage form printing software) to communicate with one or more device monitoring databases (suitably via an associated communicator, and suitably via a network such as the Internet), the device monitoring database being configured to send to the database and store (and optionally analyze and / or report) operational data collected during each printing operation (i.e. each time the printing device prints) (optionally via one or more local and / or remote computers and / or databases). As described herein, such operational data is suitably obtained / delivered by sensors associated with each given printing device, suitably sensors associated with key components of the device that may affect the quality of the final solid dosage form. The operational data may be sent to the database in real time, after printing, or at any suitable time (e.g. at night to avoid unnecessary overloading of the communication network during working hours). Such a device monitoring database may be organized with records for each printing device, and suitably may keep a log of operational data each time the printing device is operated. Suitably, each set of operational data is cross-referenced to a solid dosage form for a given patient, suitably such that if any of the operational data is deemed to be faulty, relevant interested parties may be alerted. In this way, each printing device may be monitored (whether in real time or otherwise, whether automatically or otherwise) and data submitted periodically to meet regulatory requirements. Furthermore, the central device monitoring database may trigger a response to any perceived fault of a given printing device. Furthermore, a response may be triggered which prevents the relevant faulty printing device from being used until its performance can be revalidated.

[0195] In addition, any of the one or more device monitoring databases may be accessible to interested parties, preferably securely (to maintain confidentiality of certain data), so that relevant information can be retrieved and / or analyzed as needed (e.g., if a regulatory agency wishes to check whether a given printing device has been in good condition throughout a given period of time, or if a machine maintenance professional wishes to use the data to diagnose a problem in order to restore the performance of a given printing device). Suitably, such databases may be accessed wirelessly via a network such as the Internet. Such database architectures are well known in the art.

[0196] Methods of printing solid dosage forms and / or using the apparatus

[0197] The present invention also provides a method for preparing (or printing) a solid dosage form suitably as defined herein. Suitably, the method is a method using the above-mentioned device. Therefore, the method may suitably include providing a solid dosage form printing device as defined herein.

[0198] The method suitably comprises operating the apparatus to produce a core-shell based solid dosage form on a build platform by 3D printing of the shell and dispensing the core into the shell. Suitably, such production is performed via a computer-implemented process (i.e., wherein printing and dispensing are controlled and suitably initiated by a computer connected or connectable to or in the apparatus, whether in a wired or wireless manner).

[0199] The method suitably involves printing a three-dimensional partial shell on a build platform. The partial shell is suitably an open shell. The open shell suitably comprises a shell composition, which is suitably formed by printing a shell composition (or a precursor thereof). Such printing suitably involves 3D printing, preferably FFF 3D printing. Therefore, 3D printing may include printing with one or more printing filaments, wherein at least one printing filament comprises a shell composition (or a precursor thereof) or consists of a shell composition (or a precursor thereof). The shell composition (or its precursor) is suitably printed via a structure printing nozzle of the apparatus of the present invention.

[0200] The method suitably involves dispensing the core composition (or a precursor thereof) into a partial shell or an open shell. Such dispensing suitably results in an open core-containing shell. The core composition (or a precursor thereof) is suitably dispensed via the non-structured dispenser of the apparatus of the present invention.

[0201] The method suitably relates to a closed shell, which suitably provides a complete shell around the core. Suitably, after the core composition (or its precursor) is introduced into the (partial) shell, the shell is closed. Suitably, the method relates to suitably closing an open core-containing shell by printing a closure thereon (i.e., to cover or otherwise seal the opening of the open core-containing shell). Suitably, the closure comprises a shell composition, suitably, a shell composition identical to a partial shell. Suitably, the shell composition (or its precursor) is printed to form a closure. Suitably, the shell composition (or its precursor) is printed via a structure printing nozzle, which may be identical or different from the structure printing nozzle for printing a partial shell.

[0202] The method may include one or more additional steps before, during and / or after any of the above steps. For example, the shell formed by the shell composition of the present invention can be an inner shell or an outer shell of a multi-shell solid dosage form. Therefore, the second shell and subsequent shells can be formed simultaneously with the shell of the present invention. Such additional shells can be used to customize the release profile of the active in the core, or can be used for another purpose, such as providing an inert barrier between the main shell and the core to mitigate any reaction between them. Optionally, the inner or outer surface of the main shell can be pre-treated or post-treated, whether by printing additional layers or partial layers, or by alternative coating techniques well known in the art.

[0203] In certain embodiments, the method may involve dispensing one or more additional core composition precursors or reactants into the open shell before or after the primary core composition (or its precursor) has been dispensed into the open shell. Adding additional core precursors or reactants allows reactions and transformations to occur in situ within the core. For example, a pH adjuster (e.g., an acid or alkali / base) may be dispensed into the open shell before or after the primary core composition (or precursor) to cause a pH change that results in a chemical or physical transformation, such as in situ gelation.

[0204] In alternative embodiments, dispensing of additional core precursors and / or reactants may occur simultaneously with dispensing of the primary core composition (or precursors), for example, during printing, multiple precursors may become mixed, perhaps even before reaching the interior of the open shell.

[0205] The solid dosage form produced by the method of the present invention can then be processed in a variety of ways to provide a further processed solid dosage form. For example, the solid dosage form can be enteric coated by standard enteric coating processes known in the art. Similarly, other release-controlling properties can be imparted to the solid dosage form by additional processing, such as providing a solid dosage form with one or more shells.

[0206] Although multi-stage printing—involving production of a partial shell, filling the partial shell with a core composition, and then completing (or closing) the shell—tends to result in fewer troubleshooting issues and a higher success rate, in an alternative embodiment, single-stage printing may be employed, which may suitably involve interchanging printing of the shell with dispensing of the core composition. Such single-stage printing may allow for a larger volume of core composition within the shell.

[0207] Most suitably, all steps (including any further processing steps) are performed by the printing apparatus, and suitably controlled by the same computer.

[0208] Printing open shell

[0209] Printing a three-dimensional open shell onto a build platform is suitably performed via FFF 3D printing, suitably with one or more filaments that collectively comprise a shell composition (or a precursor thereof). Most suitably, a single filament comprises or consists of a shell composition (or a precursor thereof). Such filaments are suitably printed via a structure printing nozzle as described herein.

[0210] Initially, the printing filament comprising the shell composition (or its precursor) is suitably located in a storage position in the device (or printer), suitably located on a filament reel, suitably located in a box. The printing filament is suitably delivered to the structure printing nozzle via one or more conveyors (e.g., rollers). Then, the printing filament is extruded by the structure printing nozzle (suitably, while the filament continues to be delivered from the storage position toward the nozzle). Printing by the structure printing nozzle suitably involves melting and / or softening the filament to allow the filament to be suitably deposited on the building platform in a layer-by-layer manner. Suitably, the relevant printing filament composition is solidified after being deposited on the building platform or after being deposited on the layer that has been printed on the building platform. Suitably, by wise deposition according to a predefined blueprint, a 3D shape (in this case, an open shell) is constructed in a layer-by-layer manner.

[0211] The structure printing nozzle is suitably heated at an operating temperature as described herein to facilitate melting and / or softening of the printing filament. The nozzle is suitably printing the filament at one or more operating speeds described herein.

[0212] During printing of the plurality of open shells, the structure printing nozzle is suitably moved, suitably in any or all of the X, Y, Z directions.

[0213] Once printed, the open shell is suitably placed on the build platform, suitably similar to a small cup. Suitably, the open shell includes an opening, and suitably, the opening is accessible to a dispenser of the core composition (or its precursor). Suitably, the build platform is located below the open shell, and the opening of the shell is at the top of the shell. Therefore, the open shell is suitably a container. The shell suitably includes a concave interior, which can be circular. The shell can be considered to include a wall, although in fact the shell can be a single circular continuous body.

[0214] Suitably, the plurality of open shells are printed on the build platform prior to dispensing any core composition from the non-structured dispenser.

[0215] Those skilled in the art will appreciate that the, each or any nozzle may be modified to suit the properties of the corresponding filament it is configured to print onto. The nozzle performance / design and the filament properties / composition suitably complement each other so as to facilitate controlled extrusion of the filament (whether continuous or intermittent, such as where more than one filament is used in the printing of a solid dosage form), suitably without any nozzle blockage or obstruction, and suitably without any unacceptable degradation of components within the filament during the printing process.

[0216] Dispense the cores into the open shells

[0217] The core is suitably dispensed into the one or more shells after printing the one or more (open) shells onto the build platform (suitably after a plurality of open shells have been printed onto the build platform). Suitably, the core is dispensed into the shell or each shell by dispensing the core composition (or a precursor thereof) into the open shells, which suitably results in an open shell containing the core. The core composition (or a precursor thereof) is suitably dispensed from a non-structured dispenser of the apparatus of the invention.

[0218] Suitably, the method comprises dispensing a core composition (or a precursor thereof) (suitably a predetermined amount thereof) into the or each open shell, the core composition being a fluid composition (i.e. suitably capable of flowing under gravity), such as a granular solid or a liquid (including solutions, suspensions etc.).

[0219] Suitably, the core composition (or precursor) is at a temperature of or below 90°C, suitably at a temperature of or below 75°C, suitably at a temperature of or below 60°C, suitably at a temperature of or below 50°C, suitably at a temperature of or below 40°C, more suitably at a temperature of or below 30°C, suitably at a temperature of or above 0°C, suitably at a temperature of or above 10°C during its dispensing through the non-structured dispenser.

[0220] In the case where the final core composition (formed in a solid dosage form) is different from the core composition precursor, the method may suitably involve dispensing one or more core composition precursors and / or reactants. For example, before the second core composition precursor and / or reactant is dispensed into the open shell, the first core composition precursor and / or reactant may first be dispensed into the open shell (containing the first core composition precursor and / or reactant in the open shell). In such an embodiment, the chemical reaction between the core composition precursors and / or reactants may change the entire composition. Such a chemical reaction may even change the physical form of the composition—the resulting core composition may be a solid, liquid, or even a gel. In an embodiment, one of the core composition precursors may be an active-containing core precursor, and another of the core composition precursors may be a pH adjuster (e.g., including an acid, a base, and / or a buffer) that changes the pH of the active-containing core precursor to cause any one or both of the chemical and / or physical changes. In a particular embodiment, the active-containing core precursor may be dispensed as a liquid, but may be converted into a solid or gelled core composition.

[0221] In some embodiments, the mixing of the core composition precursors and / or reactants described above can occur in a mixing chamber during dispensing (or even before the chemical reaction is slow enough to not compromise dispensing). For example, dispensing of the core composition can involve dispensing two or more core composition precursors and / or reactants into a mixing chamber before ultimately being dispensed into an open shell. In this way, more uniformity can be achieved throughout the core composition. The mixing chamber may need to be small enough to avoid accumulation of clogging material.

[0222] In a preferred embodiment, the core composition in the final solid dosage form is the same as the core composition dispensed from the apparatus of the present invention, and no subsequent modification of the composition occurs.Thus, the core suitably comprises a core composition according to that dispensed from a non-structured dispenser.

[0223] The method suitably comprises dispensing individual doses of a core composition (within each open shell) comprising between 0.1 μg and 1000 mg, suitably between 1 μg and 500 mg, suitably between 10 μg and 50 mg, suitably between 100 μg and 10 mg of the active ingredient per individual dose.

[0224] Where the core composition (or a precursor thereof) to be dispensed is a granular solid, its dispensing suitably comprises sampling the solid from a primary storage container in a suitably quantitative manner (this may be performed by extracting the granular solid from the storage container with a sampling probe or the like, or by receiving the granular solid discharged from the storage container into a container). Suitably, the sampled granular solid is suitably quantified gravimetrically (suitably, in addition to any preliminary quantification during sampling). A single dose of the quantified granular solid is then suitably dispensed into the open shell in a forcible manner (e.g., using pressure to push the solid, or using reduced pressure to pull the solid).

[0225] In contrast to the printing of shells, which are characterized by multiple printed layers, the cores are suitably distributed en bloc or in batches (i.e. as a single volume or mass directed to the same target location). Suitably, upon printing, the core composition (or its precursor) collapses and expands to the size of the open shell due to its relative fluidity. The open shell acts as a container to facilitate the method of the invention.

[0226] Where the core composition (or a precursor thereof) to be dispensed is a liquid, suitably the liquid is dispensed volumetrically, suitably via a syringe or syringe driver.

[0227] Close the shell to enclose the core

[0228] Suitably, the "filled" open shell (open shell containing a core) is closed by printing a printing composition (e.g., using filaments, where FFF 3D-printing is employed) through a structured printing nozzle as defined herein onto the "filled" open shell. The printing composition used to close the shell may be the same or different from the shell composition (or precursor) used to print the open shell, although most preferably the composition is the same and is printed via the same printing nozzle (or a similar or identical printing nozzle at another station within the overall apparatus). Most preferably, the open shell is closed using the same printing method described above in connection with printing the open shell.

[0229] Computer Implementation of the Method

[0230] The method of preparing a solid dosage form is suitably a computer implemented method, suitably as defined herein.

[0231] The method suitably involves providing a solid dosage form printing apparatus suitably as defined herein, and operating the apparatus to print a solid dosage form. Suitably, the apparatus comprises a computer or is otherwise connected to a computer. Operating the apparatus suitably involves operating a computer, which is suitably connected (whether it is wired or wireless) to or within an associated printing apparatus (so as to allow the computer to control and coordinate other parts of the apparatus, suitably including an FFF 3D printer), to cause printing of a solid dosage form.

[0232] The computer included in the device of the present invention or the computer otherwise associated with the device of the present invention can be suitably referred to as a print control computer (or print computer). The print control computer can provide different functions (and can be different entities) with other "computers" mentioned herein (such as monitoring computers and analysis computers), although a single computer can perform the functions of one or more of any combination of these computers. The print control computer suitably controls the printing of the shell composition (or precursor) by the structure printing nozzle and the distribution of the core composition (or precursor) by the non-structure dispenser. As long as different computers are used to implement each of these operations, the computer is suitably coordinated, and therefore can be considered as a part of an integral computer.

[0233] The printing of the solid dosage form is suitably controlled by a computer running according to the solid dosage form printing software, suitably based on information provided to the computer by user input (drug type, drug dosage level), databases (e.g., patient databases and / or solid dosage form databases), and / or data files (e.g., design and / or parameter files), as described herein. Suitably, the FFF 3D printer is configured to print according to instructions provided by the computer by: feeding the filament to and through its corresponding nozzle at a suitable interval and / or at a suitable rate; heating the relevant nozzle at a suitable temperature for a suitable time; and by moving the nozzle and / or the build platform so that the system's layer-by-layer printing is achieved according to the relevant information obtained and the calculations performed by the computer. Such printing is also suitably coordinated with the distribution of the core composition (or precursor), which is also controlled based on information provided to the computer using input, databases, etc. This includes coordinating the amount to be distributed according to the volume of the relevant printed shell, as well as the time of such distribution-which can only occur after the structural base (e.g., open shell) has been printed.

[0234] Feeding the filaments to and through their respective nozzles is suitably facilitated by a conveyor (or roller) as described elsewhere herein. Such a conveyor is suitably positioned along the filament flow path of a given filament, suitably between a filament source (e.g., a filament spool or box) and an extrusion nozzle to which the given filament is assigned and through which it flows.

[0235] The extrusion nozzle (including the structure printing nozzle) is suitably controlled by a computer according to the "obtained information" (e.g., design and / or other parameters) about the solid dosage form. The nozzle is suitably controlled to extrude a given filament on the building platform (or on a partially built solid dosage form on the building platform) into a pattern predefined by the "obtained information". Therefore, the nozzle or each nozzle can be controlled to switch "on" and "off" according to a predefined schedule to deliver the desired pattern in the construction of the solid dosage form. The nozzle can be switched to "on" by opening the output opening, by adjusting the operating temperature of the nozzle (e.g., increasing it so that the relevant filament melts), by operating the conveyor to feed the filament through the nozzle, or any or all combinations of the above. Of course, the nozzle can be switched to "off" by closing the output opening, by adjusting the operating temperature of the nozzle (e.g., reducing it to a temperature that does not melt the relevant filament), by operating the conveyor to limit or stop feeding the filament through the nozzle, or any or all combinations of the above. The temperature of the nozzle is suitably set and controlled by a computer according to the properties of the filament in question, as described elsewhere herein. Suitably, the operating temperature of the extrusion nozzle through which the printing filament passes is between 90°C and 220°C, more suitably between 120°C and 190°C, suitably between 165°C and 190°C, suitably between 140°C and 170°C. Suitably, the operating temperature of the extrusion nozzle through which the printing filament passes is between 80°C and 300°C, more suitably between 100°C and 220°C, suitably between 120°C and 190°C. However, the operating temperature of the extrusion nozzle may be as low as 65°C, particularly in systems employing low melting point polymers (e.g., PEG) or polymers with low glass transition temperatures. Most suitably, the extrusion nozzle temperature is set to at least 70°C. In a particular embodiment, the nozzle temperature is 110°C-160°C, suitably 110°C-130°C, suitably 130°C-150°C, suitably 135°C-145°C. Suitably, the operating temperature of the extrusion nozzle assigned to a given filament is higher than any corresponding hotmelt extrusion temperature used in forming (ie via extrusion) the given filament, suitably higher than between 30°C and 90°C, more suitably higher than between 50°C and 70°C.

[0236] The non-structural dispenser is suitably controlled by a computer according to "obtained information" (such as design and / or other parameters) about solid dosage forms. Therefore, the non-structural dispenser or each non-structural dispenser can be controlled to switch "on" and "off" according to a predefined schedule, so that the required amount is delivered to the relevant open shell of the solid dosage form during its construction. The non-structural dispenser can be switched to "on" by the activated distribution mechanism, which can suitably relate to sampling and / or distribution, depending on whether solid or liquid is distributed. Naturally, the non-structural dispenser can be switched to "off" by deactivating the aforementioned mechanism. The temperature of the core composition (or precursor) is suitably set and controlled by a computer according to the property of the core composition (or precursor) discussed, as described elsewhere herein. Suitably, the operating temperature of the non-structural dispenser is as described above. Most suitably, there is no significant heating of the non-structural dispenser or any of its parts, because lower temperatures are preferably to prevent and degrade the active ingredient located in the core composition (or its precursor).

[0237] The building platform is suitably controlled by a computer according to "obtained information" (e.g., design and / or other parameters) about the solid dosage form, suitably as described elsewhere herein. This may include controlling the operating temperature of the building platform, in particular the operating temperature of the surface of the building platform. Suitably, during printing, the operating temperature of the building platform or its surface is kept substantially constant, suitably kept at a constant temperature of + / -5°C. Such temperature control can contribute to the cooling and / or hardening of the melted wire after deposition, thereby ensuring the structural integrity of the solid dosage form when it is printed. Such temperature control can contribute to the adhesion of the developed solid dosage form to the surface of the building platform during printing. Such temperature control can contribute to the release (i.e., unsticking) of the solid dosage form after printing (e.g., the surface of the building platform can be heated or cooled, as the case may be, to reduce the adhesion of the solid dosage form to it). During printing, the build platform is suitably configured or operable to maintain a surface temperature (i.e., for the surface in contact with the solid dosage form) of less than or equal to 50°C, suitably less than or equal to 40°C, suitably less than or equal to 30°C, suitably greater than or equal to 5°C, suitably greater than or equal to 15°C.

[0238] Solid dosage form

[0239] The present invention provides a solid dosage form.The solid dosage form may be a solid dosage form obtainable, obtained or directly obtained by a process for preparing a solid dosage form as defined herein.

[0240] In certain embodiments, the solid dosage form is a pharmaceutical dosage form.

[0241] The solid dosage form suitably includes a core. The core suitably includes a core composition. The core composition suitably includes an active ingredient, suitably a pharmaceutically active ingredient, a nutrient active ingredient or a food supplement active ingredient. Most suitably, the active ingredient is a pharmaceutically active ingredient. The core is suitably distributed, preferably distributed at a relatively low temperature (as described herein about the operating temperature of the non-structural dispenser), and is therefore suitably non-printable (e.g., not printed via a 3D printing nozzle). The core composition (suitably solid, liquid or gel) is suitably contained in the shell.

[0242] The solid dosage form suitably comprises a shell, suitably a three-dimensional shell. The shell suitably surrounds the core. The shell suitably comprises a shell composition. The shell is suitably printed (e.g., printed via a 3D printing nozzle), suitably printed at a relatively high temperature (as described herein with respect to the operating temperature of the structure printing nozzle). The shell composition suitably comprises (or consists of) a 3D printing composition (e.g., a fused filament manufacturing composition), wherein the shell composition is suitably (structurally) solid.

[0243] In a particular embodiment, the solid dosage form is a capsule. Suitably, the shape of the capsule is defined by a shell. Suitably, the capsule comprises a core composition as defined herein.

[0244] Suitably, the core and shell are compatible with each other, and suitably physically and chemically inert to each other. For example, suitably, the liquid (or solid in fact) core does not substantially dissolve or disintegrate the shell or any of its components (particularly not within 14 days, suitably not within 30 days, suitably not within 12 months), and vice versa. In addition, suitably, the core does not chemically react with the shell (particularly not within 14 days, suitably not within 30 days, suitably not within 12 months). Therefore, suitably, each of the core and shell is substantially stable in the solid dosage form. Suitably, the solid dosage form remains pharmaceutically acceptable and / or feasible for at least 14 days after its manufacture, suitably for at least 30 days, suitably for at least 12 months.

[0245] Suitably, the core is physically separated from the shell. Suitably, the core (or a portion thereof) is physically movable relative to the shell, or at least movable in the presence of free internal space. For example, in the case of a liquid, the liquid is suitably free to move within the shell under agitation of the solid dosage form; and in the case of a granular solid, the particles are suitably free to move within the shell under agitation of the solid dosage form. In some cases, when the solid dosage form is stirred, an audible shaking (for a liquid core) or vibration (for a solid core) may be heard.

[0246] Based on the shell having a layered structure (by virtue of the 3D printing mechanism printing layer by layer) and the core having a non-layered structure (by virtue of the core having been integrally distributed into the shell), the core can be suitably discerned from the shell (e.g. if a cross-section of the solid dosage form is taken).

[0247] The solid dosage form of the present invention is suitably for oral administration.Most preferably, the solid dosage form is a capsule, most preferably a pharmaceutical capsule.

[0248] Solid dosage forms of the present invention can be immediate release dosage forms, delayed release dosage forms (e.g., with enteric coatings or shells) or sustained release dosage forms. The release profile of the solid dosage form can depend on the shell, core, or any other shell (e.g., around the main shell characterized by the shell composition as defined herein). If the core comprises microcapsules or coated particles, such coatings may affect the release profile. However, most suitably, the shell is customized to affect the active release profile.

[0249] The longest dimension of the solid dosage form (D max ) (e.g., whether in the X, Y or Z direction) is suitably greater than or equal to 3 mm, suitably greater than or equal to 5 mm, suitably greater than or equal to 8 mm, suitably greater than or equal to 10 mm, suitably greater than or equal to 12 mm. The longest dimension of the solid dosage form is suitably less than or equal to 30 mm, suitably less than or equal to 25 mm, suitably less than or equal to 20 mm, suitably less than or equal to 15 mm.

[0250] The shortest dimension of the solid dosage form (D min The shortest dimension of the solid dosage form is suitably less than or equal to 30 mm, suitably less than or equal to 25 mm, suitably less than or equal to 20 mm, suitably less than or equal to 15 mm, suitably less than or equal to 10 mm, suitably less than or equal to 8 mm.

[0251] Volume of solid dosage form (V sdf , suitably in accordance with the space defined by the shell, suitably up to and including the shell surface) suitably greater than or equal to 3 mm 3 , suitably greater than or equal to 5mm 3 , suitably greater than or equal to 10mm 3 , suitably greater than or equal to 50mm 3 , suitably greater than or equal to 100mm 3 , suitably greater than or equal to 200mm 3The volume of the solid dosage form is suitably less than or equal to 500 mm 3 , suitably less than or equal to 300mm 3 , suitably less than or equal to 250mm 3 , suitably less than or equal to 150mm 3 , suitably less than or equal to 50mm 3 .

[0252] The solid dosage forms of the present invention are advantageously customizable with respect to the type / nature of the dose of the active ingredient, the dose of the active ingredient within the solid dosage form (whether it is an absolute dose per solid dosage form or the concentration of the active within the dosage form), the mass / volume of the solid dosage form (which can typically be adapted to vary the absolute dose of the active without varying the concentration of the active within the dosage form), the active release profile (which can be varied by judicious use and / or distribution of suitable excipients, e.g., a core-shell arrangement for delayed or sustained release), or shape and appearance (including novel shapes, colors, and patterns, such as those that can help promote medication compliance for a particular patient).

[0253] Preferred many features of solid dosage forms are described elsewhere herein. For example, features described with respect to methods of producing solid dosage forms may suitably reflect features of the solid dosage form itself (e.g., layer height). Suitably, the solid dosage form comprises ingredients provided by the filaments used in its formation (e.g., in the shell), and may be considered to comprise the relevant filament composition.

[0254] The shell of the solid dosage form has an average thickness of suitably greater than or equal to 1 μm, suitably greater than or equal to 10 μm, suitably greater than or equal to 100 μm, suitably greater than or equal to 500 μm, suitably greater than or equal to 1 mm. The shell of the solid dosage form has an average thickness of suitably less than or equal to 5 mm, suitably less than or equal to 2 mm, suitably less than or equal to 1 mm, suitably less than or equal to 600 μm.

[0255] Suitably, the solid dosage form of the present invention comprises greater than or equal to 0.5 wt% of the active ingredient, suitably greater than or equal to 1 wt% of the active ingredient, suitably greater than or equal to 5 wt% of the active ingredient, suitably greater than or equal to 9 wt% of the active ingredient, suitably greater than or equal to 19 wt% of the active ingredient, suitably greater than or equal to 39 wt% of the active ingredient. Suitably, the solid dosage form of the present invention comprises less than or equal to 60 wt% of the active ingredient, suitably less than or equal to 50 wt% of the active ingredient, suitably less than or equal to 30 wt% of the active ingredient. Suitably, after the active ingredient, the weight balance of the solid dosage form consists essentially of carriers, diluents and / or excipients (all of which may be considered to constitute "excipients").

[0256] Suitably, the core accounts for greater than or equal to 1 wt% of the solid dosage form as a whole, suitably greater than or equal to 3 wt%, suitably greater than or equal to 5 wt%, suitably greater than or equal to 10 wt%, suitably greater than or equal to 20 wt%, suitably greater than or equal to 50 wt%, suitably greater than or equal to 60 wt%. Suitably, the core accounts for less than or equal to 70 wt% of the solid dosage form as a whole, suitably less than or equal to 55 wt%, suitably less than or equal to 25 wt%, suitably less than or equal to 15 wt%, suitably less than or equal to 5 wt%. In the solid dosage form, the shell can suitably include less weight than the core.

[0257] Suitably, the core of the or each solid dosage form has a weight greater than or equal to 1 mg, suitably greater than or equal to 5 mg, suitably greater than or equal to 10 mg, suitably greater than or equal to 50 mg, suitably greater than or equal to 80 mg. Suitably, the core of the or each solid dosage form has a weight less than or equal to 1000 mg, suitably less than or equal to 500 mg, suitably less than or equal to 250 mg, suitably less than or equal to 100 mg.

[0258] Suitably, the volume of the core (V core ) accounts for the total volume of the solid dosage form (V sdf ) is greater than or equal to 0.1%, suitably greater than or equal to 1%, suitably greater than or equal to 2%, suitably greater than or equal to 4%. Suitably, the volume of the core (V core ) accounts for the total volume of the solid dosage form (V sdf ) is less than or equal to 50%, suitably less than or equal to 20%, suitably less than or equal to 10%, suitably less than or equal to 6%.

[0259] Suitably, the volume of the empty space (V empty , i.e. excluding the shell and the core) accounts for the total volume of the solid dosage form (V sdf) is greater than or equal to 0.1%, suitably greater than or equal to 1%, suitably greater than or equal to 10%, suitably greater than or equal to 20%, suitably greater than or equal to 50%.

[0260] Shell, shell composition, shell silk and shell silk composition

[0261] The shell is suitably a shell composition or includes a shell composition (i.e., is formed into a shell). The shell is suitably solid (solid). The composition of the shell is suitably (substantially) the same as the composition of the material printed from the structure printing nozzle. The shell is suitably formed by a shell printing filament (e.g., FDM or FFF filament), and therefore the shell is suitably a shell silk composition or includes a shell silk composition, suitably a FFF silk composition. Suitably, the composition of the shell is (substantially) the same as the composition of the shell silk. Therefore, any definition related to the composition of the shell silk herein (e.g., a shell silk composition) can be equally applicable to the composition of the shell itself (e.g., a shell composition), even for an embodiment in which the shell is printed by a technique other than silk printing technology. However, the shell composition can be considered to be a shell silk composition of printing defined herein, because in some cases (e.g., in the case of a certain degree of chemical change occurring in the shell composition during printing), the process of printing can better describe the product.

[0262] Although the shell may be continuous or shaped, the shell may be considered to include an opening shell and a closure (or a base shell and a lid). The overall dimensions of the solid dosage form are suitably defined entirely by the shell.

[0263] The shell composition suitably comprises one or more shell polymers, suitably pharmaceutically acceptable polymers (or GRAS approved polymers). The shell composition may comprise one or more thermoplastics. The shell composition may comprise one or more pharmaceutically acceptable polymers selected from the group consisting of (alkyl) polyacrylates, silicones, polyurethanes, polyolefins (e.g., polystyrene), polyalkylene glycols, polyvinyl alcohol, polyamides, acrylonitrile butadiene styrene (ABS), polylactic acid (PLA), polyglycolide, nylon and / or copolymers or mixtures thereof. This list is by no means exhaustive.

[0264] Shell filaments (for printing of shells) and shell filament compositions may be as described in paragraphs

[00331] to

[00340] of WO2016 / 038356 (by the present applicant), which is incorporated herein by reference. Such shell filament compositions may include one or more of the following: shell polymers identical to those described in paragraphs

[00289] to

[00302] of the same document, fillers as described in paragraphs

[00303] to

[00304] , plasticizers as described in paragraphs

[00305] to

[00312] , and other ingredients as described in paragraphs

[00313] to

[00317] . In addition, the features of shell filaments and shell filament compositions may be as described in paragraphs

[00244] to

[00270] , provided that these paragraphs apply to the "additional filament compositions" described in paragraphs

[00331] to

[00340] of that document.

[0265] Shell filaments, shell filament compositions and final shell compositions suitably include meltable components. Shell compositions may also include infusible components to alleviate nozzle clogging. Suitably, a "meltable" component is a component that melts (or undergoes a glass transition to soften) at a specified operating temperature of any corresponding 3D printer extrusion nozzle configured to process the filament, and an "infusible" component is suitably a component that does not melt (or does not undergo a glass transition) at the same temperature. Suitably, a "meltable" component may be a mixture of components that melt together or undergo a glass transition as a mixture-such as a shell polymer and a plasticizer. However, an "infusible" component is more likely to be a separate component with a different melting point or glass transition temperature. Suitably, a meltable component has a melting point (or T ) of 220°C or less, suitably 150°C or less, suitably 100°C or less, suitably 80°C or less, suitably 60°C or less. g Suitably, the meltable component has a melting point (or T) greater than or equal to 20°C, suitably greater than or equal to 30°C, suitably between 30°C and 65°C, suitably between 30°C and 35°C. g —That is, at least one T g Suitably, the non-meltable component has a melting point (or T ) at or above 150°C, suitably at or above 200°C, suitably at or above 500°C, suitably at or above 1000°C. g ).

[0266] As explained above, references to "meltable" components and "non-meltable" components encompass "softenable" components and "non-softenable" components, respectively, in which the components "soften" rather than "melt" at a particular temperature. Thus, references to melting points in this context may additionally or alternatively relate to glass transition temperatures. Such glass transitions are particularly applicable to thermoplastic components. Thus, a "meltable" component may be a thermoplastic component, suitably whose glass transition temperature (the temperature at which the thermoplastic component softens rather than melts) is lower than the temperature to which the component is exposed (e.g. during printing).

[0267] Each of the various filament components described herein is suitably a meltable component or a non-meltable component (not both). For example, the shell polymer is suitably a meltable component and is suitably selected to undergo melting or glass transition during printing. In contrast, fillers (e.g., tricalcium phosphate, talc, etc.) are suitably non-meltable components and are suitably selected to remain solid during printing. Despite the contrasting melting / glass transition properties of the various components, suitably, the filament itself has a characteristic glass transition temperature. Suitably, the characteristic glass transition temperature is measurable using the well-known techniques described herein and elsewhere and is the result of a combination of components. Various concentration (wt%) ratios of meltable component: non-meltable component can provide viable filaments for 3D printing. Suitably, the ratio of meltable component: non-meltable component is between 1:10 and 10:1, more suitably between 3:7 and 7:3, suitably between 4:6 and 6:4, wherein suitably the meltable components collectively include all relevant meltable components (e.g. shell polymer, plasticizer, etc.) and the non-meltable components include all relevant non-meltable components (e.g. fillers, lubricants, etc.).

[0268] The shell filament is suitably sufficiently stiff to enable it to be feasibly fed (at a consistent rate) to and through a corresponding extrusion nozzle within a printing device or 3D printer. The active shell filament is suitably sufficiently stiff to avoid the filament becoming stretched during printing. However, the filament is suitably not too stiff that the nozzle operating temperature required to extrude the filament would reduce the content of the component (e.g. resulting in a change in composition of greater than or equal to 1 wt%).

[0269] The shell filament is suitably sufficiently flexible and / or soft to enable it to be extruded (at a consistent rate) from a corresponding extrusion nozzle within a printing device or 3D printer. The shell filament is suitably sufficiently flexible and / or soft to allow the filament to be feasibly wound / coiled around a filament spool.

[0270] The shell filament is suitably neither too brittle (and prone to breaking during printing / winding) nor too flexible (preventing feasible transport thereof through a printing apparatus or 3D printer). The shell filament composition and dimensions (e.g., thickness) of the filament can be judiciously varied using the principles taught in the present disclosure to obtain an optimal filament structure.

[0271] The shell filaments suitably have a thickness (i.e., diameter or maximum thickness) between 0.1 mm and 5 mm, suitably between 0.5 mm and 4 mm, more suitably between 1 mm and 3 mm, most suitably between 1.5 mm and 2 mm. In a specific embodiment, the shell filaments have a thickness of about 1.75 mm. However, the filament thickness can be adjusted to accommodate the extrusion nozzle (particularly the size / diameter of its corresponding opening) through which they will be extruded.

[0272] Suitably the shell filament is capable of being wound (or wrapped) around a spool, suitably having a hub diameter of about 20 cm, suitably having a hub diameter of about 10 cm, suitably about 5 cm, suitably about 2.5 cm, suitably about 1 cm, suitably without crushing and / or stretching.

[0273] The shell filaments suitably have a glass transition temperature (T ) between 20°C and 200°C, suitably between 45°C and 165°C, or suitably between -10°C and 165°C. g ).

[0274] Suitably, the shell silk is judiciously tailored with the right proportions and types of ingredients to produce a fiber with the desired T g and / or melting point of the filament to minimize the corresponding nozzle operating temperature required for extrusion.

[0275] The shell filaments (and therefore the shell composition) suitably comprise a shell polymer. The shell polymer is suitably a meltable component, or otherwise has properties associated with meltable components as defined herein. The shell filaments optionally comprise a plasticizer. The shell filaments optionally comprise a filler, wherein suitably the filler is a non-meltable component, or otherwise has properties associated with non-meltable components as defined herein. In a specific embodiment, the shell filaments comprise a shell polymer and a plasticizer. In a specific embodiment, the shell filaments comprise a shell polymer and a filler (suitably non-meltable as defined herein). In a specific embodiment, the shell filaments comprise a shell polymer, a plasticizer, and a filler.

[0276] Suitably, the shell filaments of the present invention comprise greater than or equal to 10 wt% of the shell polymer (suitably excluding any plasticizer), suitably greater than or equal to 20 wt%, suitably greater than or equal to 30 wt%, suitably greater than 50 wt%, suitably greater than or equal to 70 wt%, suitably greater than or equal to 79 wt%. Suitably, the shell filaments of the present invention comprise less than or equal to 99 wt% of the shell polymer (suitably excluding any plasticizer), suitably less than or equal to 95 wt%, suitably less than or equal to 90 wt%, suitably less than or equal to 80 wt%, suitably less than or equal to 60 wt%.

[0277] Suitably, the shell wire of the present invention comprises greater than or equal to 0.1wt% of plasticizer, suitably greater than or equal to 1wt%, suitably greater than or equal to 3wt%, suitably greater than or equal to 4wt%, suitably greater than 9wt%, suitably greater than or equal to 15wt%. Suitably, the shell wire of the present invention comprises less than or equal to 50wt% of plasticizer, suitably less than or equal to 40wt%, suitably less than or equal to 30wt%, suitably less than or equal to 20wt%, suitably less than or equal to 11wt%.

[0278] Suitably, the shell wire of the present invention comprises greater than or equal to 1wt% filler, suitably greater than or equal to 5wt%, suitably greater than or equal to 10wt%, suitably greater than 20wt%, suitably greater than or equal to 30wt%. Suitably, the shell wire of the present invention comprises less than or equal to 70wt% filler, suitably less than or equal to 60wt%, suitably less than or equal to 50wt%, suitably less than or equal to 40wt%, suitably less than or equal to 35wt%.

[0279] In specific embodiments, the shell filaments (and thus the shell composition and / or shell filament composition) comprise or consist of:

[0280] 10 wt % to 90 wt % shell polymer;

[0281] and optionally:

[0282] 1 wt% to 30 wt% of a plasticizer; and / or

[0283] 1 wt% to 60 wt% of filler.

[0284] In specific embodiments, the shell filaments (and thus the shell composition and / or shell filament composition) comprise or consist of:

[0285] 30 wt% to 80 wt% shell polymer;

[0286] and optionally:

[0287] 5wt% to 20wt% of a plasticizer; and / or

[0288] 10wt% to 50wt% filler.

[0289] In specific embodiments, the shell filaments (and thus the shell composition and / or shell filament composition) comprise or consist of:

[0290] 40 wt% to 60 wt% shell polymer;

[0291] and optionally:

[0292] 10 wt% to 20 wt% of a plasticizer; and / or

[0293] 30wt% to 40wt% filler.

[0294] In specific embodiments, the shell filaments (and thus the shell composition and / or shell filament composition) comprise or consist of:

[0295] 40 wt% to 60 wt% shell polymer;

[0296] 10 wt% to 20 wt% of a plasticizer; and

[0297] 30wt% to 40wt% filler.

[0298] Shell polymer

[0299] Any suitable polymer may be used.

[0300] The melting point (or glass transition temperature) of the shell polymer is suitably less than that of the active ingredient, suitably at least 20° C. less, more suitably at least 40° C. less, more suitably at least 50° C. less. The shell polymer suitably has a melting point between 140° C. and 250° C., more suitably between 150° C. and 200° C., most suitably between 155° C. and 175° C.

[0301] Suitably, the shell polymer has a specific heat of between 0.1 cal / g°C and 1 cal / g°C, most preferably between 0.3 cal / g°C and 0.5 cal / g°C.

[0302] The shell polymer suitably has a density between 1.1 g / mL and 1.6 g / mL, most preferably between 1.2 g / mL and 1.4 g / mL.

[0303] The shell polymer suitably has a glass transition temperature below the melting point of the active ingredient, suitably at least 20°C below, more suitably at least 40°C below, more suitably at least 50°C below.

[0304] The shell polymer (particularly where an immediate release solid dosage form is desired) is suitably selected from polymers (suitably cationic or neutral polymers or copolymers) having a viscosity of no more than 50 mPa.s, suitably no more than 30 mPa.s, suitably no more than 10 mPa.s, although suitably having a viscosity of at least 1 mPa.s - most suitably a viscosity between 2 mPa.s and 8 mPa.s. The shell polymer (particularly where an immediate release solid dosage form is desired) is suitably selected from polymers having a molecular weight of at least 20,000 g / mol, more suitably at least 35,000 g / mol, more suitably at least 45,000 g / mol, although suitably less than 1,000,000 g / mol, more suitably less than 100,000 g / mol - most suitably a molecular weight between 35,000 g / mol and 65,000 g / mol. The shell polymer (particularly where an immediate release solid dosage form is desired) is suitably selected from polymers having a glass transition temperature (Tg) of at most 100°C, suitably at most 80°C, suitably at most 50°C, although suitably at least -10°C, more suitably at least 35°C - most suitably a Tg between 30°C and 60°C. In some embodiments, the shell polymer may not have such a glass transition temperature, although the observed softening may still occur. The shell polymer (particularly where an immediate release solid dosage form is desired) is suitably a (optionally alkyl-, suitably methyl- or ethyl-) acrylate, methacrylate and / or ethacrylate copolymer (suitably comprising amine-containing monomer units), which suitably has a viscosity between 2mPa.s and 8mPa.s, suitably has a molecular weight between 35,000g / mol and 65,000g / mol and / or suitably has a Tg between 30°C and 60°C. In a particular embodiment, the copolymer of interest is poly(butyl methacrylate-co-(2-dimethylaminoethyl)methacrylate-co-methyl methacrylate), suitably in a 1:2:1 molar ratio of the monomers (+ / - 5% molar value for each ratio). The shell polymer is suitably Eudragit E.

[0305] The shell polymer (particularly where an extended release solid dosage form is desired) is suitably selected from polymers having a viscosity of no more than 30 mPa.s, suitably no more than 20 mPa.s, suitably no more than 16 mPa.s, although suitably having a viscosity of at least 1 mPa.s - most suitably a viscosity between 1 mPa.s and 15 mPa.s. The shell polymer (particularly where an extended release solid dosage form is desired) is suitably selected from polymers having a molecular weight of at least 10,000 g / mol, more suitably at least 250,000 g / mol, more suitably at least 30,000 g / mol, although suitably less than 100,000 g / mol, more suitably less than 40,000 g / mol - most suitably a molecular weight between 29,000 g / mol and 35,000 g / mol. The shell polymer (particularly where an extended release solid dosage form is desired) is suitably selected from polymers having a glass transition temperature (Tg) of at most 100°C, suitably at most 80°C, suitably at most 70°C, although suitably at least 40°C, more suitably at least 50°C - most suitably a Tg between 55°C and 70°C. In some embodiments, the shell polymer may not have such a glass transition temperature, although the observed softening may still occur. The shell polymer (particularly where an extended release solid dosage form is desired) is suitably a (optionally alkyl-, suitably methyl- or ethyl-) acrylate, methacrylate and / or ethacrylate copolymer (suitably comprising amine-containing monomer units), which suitably has a viscosity between 1 mPa.s and 15 mPa.s, suitably has a molecular weight between 29,000 g / mol and 35,000 g / mol and / or suitably has a Tg between 55°C and 70°C. In a particular embodiment the copolymer of interest is poly(ethyl acrylate-co-methyl methacrylate-co-trimethylammonioethyl methacrylate chloride), suitably in a molar ratio of 1:2:0.2 (+ / - 5% molar value for each ratio). The shell polymer is suitably Eudragit RL.

[0306] The shell polymer (particularly where a delayed release solid dosage form is desired) is suitably selected from polymers having a viscosity of at least 20 mPa.s, suitably at least 40 mPa.s, suitably at least 50 mPa.s, although suitably having a viscosity of no more than 300 mPa.s, suitably no more than 210 mPa.s - most suitably a viscosity between 40 mPa.s and 210 mPa.s. The shell polymer (particularly where a delayed release solid dosage form is desired) is suitably selected from polymers having a molecular weight of at least 10,000 g / mol, more suitably at least 15,000 g / mol, although suitably less than 400,000 g / mol - in particular embodiments, the molecular weight is between 10,000 g / mol and 25,000 g / mol, and in other embodiments, the molecular weight is between 100,000 g / mol and 350,000 g / mol. The shell polymer (particularly where a delayed release solid dosage form is desired) is suitably selected from polymers having a glass transition temperature (Tg): at least 80°C, suitably at least 90°C, suitably at least 100°C, although suitably up to 200°C, more suitably up to 160°C - most suitably a Tg between 90°C and 160°C. In some embodiments, the shell polymer may not have such a glass transition temperature, although the observed softening may still occur. The shell polymer (particularly where a delayed release solid dosage form is desired) is suitably selected from the following:

[0307] (optionally alkyl-, suitably methyl- or ethyl-)acrylate, methacrylate and / or ethacrylate polymer or copolymer (suitably free of any amine-containing monomer units), suitably having a molecular weight of 200 g / cm3 at 90 mPa.s and 210 g / cm3 at 100 mPa.s.

[0308] mPa.s, suitably having a molecular weight between 100,000 g / mol and 350,000 g / mol, and

[0309] and / or suitably having a glass transition temperature between 90°C and 140°C; wherein the corresponding polymer or copolymer is suitably selected from: poly(methacrylic acid-co-ethyl acrylate), suitably the molar ratio of each monomer is 1:1 (for the molar value of each ratio + / - 5%); poly(methacrylic acid-co-methyl methacrylate), suitably the molar ratio of each monomer is 1:1 (for the molar value of each ratio + / - 5%); poly(methacrylic acid-co-methyl methacrylate), suitably the molar ratio of each monomer is 1:2 (for the molar value of each ratio + / - 5%); or

[0310] Cellulose or a cellulose derivative, suitably a hydroxypropylmethylcellulose (HPMC) derivative, most suitably hydroxypropylmethylcellulose acetate (HPMC) succinate (HPMCAS), suitably having a molecular weight between 10,000 g / mol and 25,000 g / mol and / or suitably having a temperature between 100°C and 145°C (or suitably at 100°C

[0311] and 165° C.); wherein the relevant HPMCAS is suitably selected from Aqoat LG, Aqoat MG and / or Aqoat HG. However, suitably the HPMC derivative may also include hydroxypropyl methylcellulose phthalate (HPMCP), such as its HP-50, HP-55 and HP-55S grades.

[0312] In principle, any suitable polymer may be used, including any one or more selected from: (optionally alkyl-, suitably methyl- or ethyl-)acrylate, methacrylate and / or ethacrylate copolymers (suitably comprising amine-containing monomer units); (optionally alkyl-, suitably methyl- or ethyl-)acrylate, methacrylate and / or ethacrylate polymers or copolymers (suitably free of any amine-containing monomer units); cellulose or a cellulose derivative; polyvinyl alcohol (PVA); poly(lactic-co-glycolic acid) (PLGA); and / or any suitable pharmaceutically acceptable carrier.

[0313] The shell polymer is suitably selected from Eudragit E, Eudragit NE, HPC SSL, Eudragit RS, Eudragit RL, HPC SL, HPC M, HPC H, Eudragit L100-55, Eudragit L100, Eudragit S100, Aqoat LG, Aqoat MG, Aqoat HG and / or polyvinyl alcohol (PVA), or any combination of any of the foregoing.

[0314] In some embodiments, shell polymers such as polyvinyl pyrrolidone polymers or polyvinyl pyrrolidone derived polymers can be used, particularly in cases where the active ingredient has limited solubility in a target solubilisation medium (e.g. in vivo). Such polymers can contribute to the dissolution of active ingredients that otherwise may exhibit limited solubility. In a particular embodiment, PVP K29-32 (Povidone) can be used. When present, suitably, PVP or a PVP-based polymer is present in (e.g., a filament, a solid dosage form or a core) at a concentration between 20wt% and 80wt%, suitably at a concentration between 40wt% and 60wt%, suitably at a concentration of 45wt%-55wt%. PVP and PVP-based shell polymers can be used together with one or more fillers, and optionally together with other ingredients such as plasticizers. It is also possible to use or selectively use a mixture of different PVP or PVP-based polymers (e.g., PVP of different molecular weights).

[0315] In some embodiments, polyalkylene glycol and polyalkylene glycol derived polymers can be used as shell polymers. In specific embodiments, polyalkylene glycol or polyalkylene glycol derived shell polymers are polyethylene glycol (PEG) or polyethylene glycol derived shell polymers. Suitably, no matter where PEG or PEG-based shell polymers are deployed, at least a portion of PEG or PEG-based shell polymers have a molecular weight of at least 100,000 g / mol, although suitably up to 1,000,000 g / mol. However, mixtures of different polyalkylene glycols and polyalkylene glycol derived polymers (such as PEG or PEG-based shell polymers) can be incorporated into silk and / or corresponding dosage forms. For example, high molecular weight PEG can be used together with relatively low molecular weight PEG to achieve optimal performance balance. Higher molecular weight PEG and PEG-based polymers (such as M w ≥80,000) can be used as polymer molecules, while lower molecular weight PEG and PEG-based polymers (e.g., M w 200-20000) can be used as a plasticizer and / or solubility enhancer. Increasing the proportion of lower molecular weight PEG may reduce the T of the resulting silk. g In addition, increasing the lower M w The proportion of PEG also contributes to accelerated drug release.Suitably, any PEG or PEG-based shell polymer is used with one or more fillers, although such polymers may or may not be used with a non-melting component.

[0316] Plasticizers

[0317] The shell filaments (and thus the shell compositions) may suitably include a plasticizer. Such a plasticizer may improve the quality of the filament (e.g., in terms of smoothness, flexibility, fluidity when extruded). A plasticizer may be used to lower the glass transition (or softening) temperature of the filament (or polymer), and may therefore allow the use of lower extrusion nozzle operating temperatures during printing and / or forming of the filament.

[0318] In general, if the filament has a glass transition temperature (Tg) that is too high, it may be too brittle (e.g., cannot be wound onto a filament spool) for an FFF 3D printer to handle (i.e., without destroying the filament), and / or may require very high extrusion nozzle operating temperatures, such that degradation of components in the filament may occur. In the case of a filament with too low a glass transition temperature, the filament may be too soft and / or flexible for an FFF 3D printer to handle, too easily distortable for consistent printing, and produce poor shape control and an incoherent solid dosage form product. Plasticizers may be used as additives to optimize the properties of the filament by obtaining an optimal glass transition or softening temperature and achieving an appropriate balance of properties.

[0319] The filaments may include any suitable plasticizer.A number of pharmaceutically acceptable plasticizers are known in the art for use in forming pharmaceutical solid dosage forms.

[0320] In particular embodiments, the plasticizer may be selected from one or more of triethyl citrate (TEC), glycerol, castor oil, oleic acid, glycerol, triacetin, and polyalkylene glycols (eg, polyethylene glycol or polypropylene glycol, such as PEG400).

[0321] Depending on the specific active ingredient and shell polymer, some plasticizers may be more suitable than others. Specific combinations that provide excellent properties include:

[0322] TEC and / or triacetin (0.5-10 wt% in the overall silk) plasticizers combined with cellulose-based polymers such as HPC, HPMC and HPMCAS;

[0323] Glycerol plasticizer combined with PVA-based polymers;

[0324] • TEC plasticizer in combination with a (optionally alkyl-, suitably methyl- or ethyl-) acrylate, methacrylate and / or ethylacrylate polymer or copolymer (suitably 0.5 wt% - 30 wt% thereof within the overall filament).

[0325] More than one plasticizer (optionally as defined herein) may be used.

[0326] In alternative embodiments, instead of incorporating the plasticizer into the filament, the plasticizer may be coated on the surface of the relevant filament, suitably so as to provide the desired ductility and feasible nozzle operating temperature. In particular embodiments, during the printing process, the filament (with or without plasticizer therein) may be conveyed toward the respective extrusion nozzle via a plasticizer dispenser, which coats the surface of the filament (or a portion thereof) with the plasticizer. Thus, in particular embodiments, the shell filament may suitably include or be in contact with a plasticizer before it is extruded from the respective extrusion nozzle.

[0327] Fillers

[0328] As mentioned above, suitably, the shell filaments of the present invention include one or more fillers suitably in the stated amount. Suitably, the filler is included with the shell polymer (such as those described herein) and optionally also with other excipients such as plasticizers, adhesives and the like. By following the teaching of this specification, it is possible to achieve an ideal balance between the components. Typically, one or more fillers are included in the filaments or filament compositions to enhance the filaments produced, and thereby contribute to their generation and processing during 3D printing. However, too much filler may lead to a certain degree of brittleness, which can be mitigated by judicious use of other ingredients (such as plasticizers and the like that can be used to soften the filaments), by reducing the proportion of the filler and / or changing the properties of the filler (such as its melting point).

[0329] Many fillers are known in the pharmaceutical and nutraceutical fields, and any of these can be deployed where appropriate or desired for a particular drug or nutraceutical. Suitably, at least one (preferably all) of the fillers has a melting point that exceeds the relevant operating temperature of the components (e.g., print nozzles, extrusion nozzles, and / or heated conveyors or feeders) with which the filament is in contact. Suitably, the filler is substantially inert, and / or suitably has minimal or no interaction with other components (e.g., drugs or polymers) in the filament or dosage form. Talc is an ideal filler for use in the filaments and dosage forms of the present invention, particularly in combination with PVP or PEG polymers.

[0330] Other Ingredients

[0331] The shell filaments may contain one or more other ingredients. The other ingredients may suitably include one or more excipients, excipient carriers and / or diluents, all of which may be included in the shell filaments.

[0332] In particular, the one or more other ingredients within the printing filament may be selected from one or more fillers / diluents, anti-adherents, binders, disintegrants, lubricants, glidants, flavors, preservatives, sweeteners and coatings.

[0333] Suitable anti-adhesives may include magnesium stearate. Suitable diluents / fillers may include vegetable cellulose, calcium hydrogen phosphate, vegetable fats and oils, lactose, sucrose, glucose, mannitol, sorbitol, calcium carbonate, magnesium stearate and / or microcrystalline cellulose. Suitable binders may include carbohydrates; polysaccharides / derivatives thereof, such as starch, cellulose or modified cellulose such as microcrystalline cellulose and cellulose ethers such as hydroxypropyl cellulose, hydroxypropyl methylcellulose and derivatives thereof; sugar alcohols, such as xylitol, sorbitol or maltitol; synthetic polymers, such as polyvinyl pyrrolidone (PVP), polyethylene glycol (PEG) ...). Suitable disintegrants may include cross-linked polyvinyl pyrrolidone (crospovidone), cross-linked sodium carboxymethyl cellulose, cross-linked sodium carboxymethyl cellulose, modified sodium starch and / or glycolate. Suitable lubricants may include silicon dioxide; fats, such as vegetable stearin; magnesium stearate or stearic acid; and / or talc. Suitable glidants may include fumed silicon dioxide, talc, magnesium carbonate and / or colloidal silicon dioxide. Suitable coatings may include tablet coatings to protect tablet ingredients from moisture degradation in the air and to make large or unpleasant tasting tablets easier to swallow (e.g., cellulose ether hydroxypropyl methylcellulose (HPMC) film coatings; synthetic polymers, shellac, corn proteinzein or other polysaccharides, gelatin; enteric coatings, e.g., including fatty acids, waxes, shellac, plastics, plant fibers). The general categories of excipients are well understood by those skilled in the art.

[0334] In a particular embodiment, the shell filament comprises talc (the talc is suitably a filler as mentioned above). The talc can be used as a non-melting particle to improve the performance of the extrusion nozzle. The filament or final solid dosage form (or its core) may comprise between 10wt% and 50wt%, preferably 40wt% talc, as too much lubricant may result in poor adhesion of the solid dosage form to the build platform during printing.

[0335] Such excipients may be selected to accommodate the properties of the final solid dosage form, the properties of the filament, or both, or a judicious compromise between the two. For example, in the case of solid dosage forms, excipients may be selected to facilitate administration to the target patient population by the intended route; improve dosing compliance; consistency and control of drug bioavailability; to enable bioavailability; improve active ingredient stability, including preventing degradation; to ensure a robust and reproducible physical product. In the case of filaments (e.g., for use in FFF 3D printing), excipients may be selected to optimize the physical form and / or stability of the filaments; to ensure a robust and reproducible physical product; the flexibility and rigidity of the filaments (an optimal balance between the flexibility and rigidity of the filaments is desirable to ensure that the filaments can be successfully delivered to the extrusion nozzle but then easily extruded from the nozzle); to enable production of an optimal solid dosage form (e.g., based on the above points).

[0336] Silk coating

[0337] The filament may suitably include a protective filament coating, which is suitably coated on the outermost surface of the filament. Such a filament coating may be deployed whether printing with a single head or multiple heads (e.g. dual head), although such a coating may be most applicable in the case of multi-head printing, where the filament is at increased risk of prolonged exposure to heat (and consequent filament degradation) while temporarily stationary (when not being printed) within its respective nozzle.

[0338] The protective silk coating is suitably derived from a corresponding protective silk coating composition. Suitably, the protective silk coating comprises pharmaceutically and / or nutritionally acceptable ingredients. Suitably, the protective silk coating is a liquid or oil, suitably having a high boiling point (e.g., at least 150°C, suitably at least 170°C, suitably at least 220°C). The coating suitably reduces degradation of the silk when exposed to heat. The protective silk coating (or composition) suitably comprises a liquid and / or oil. Suitably, the protective coating does not prevent the associated silk from melting or undergoing a glass transition at the operating temperature of the extrusion nozzle.

[0339] The present inventors have found that the use of olive oil BP, oleic acid, arachidonic acid and glycerol helps in coordination between the dual nozzles and avoids degradation of the drug-polymer filaments. The use of such components to coat the filaments is believed to provide a protective layer on the surface of the filaments. Such components also have relatively high melting points and do not degrade at the processing temperature of the 3D nozzle.

[0340] core

[0341] The core is suitably a non-printing composition.The core is suitably dispensed in bulk (eg a predetermined volume or mass which is dispensed to a specific target location), and suitably does not feature a layered structure.

[0342] The core comprises a core composition or is composed of a core composition. The core composition is not printable via a structural printing nozzle, and the shell can be printed by the structural printing nozzle. The core composition suitably comprises one or more active ingredients. The core composition can be any suitable pharmaceutical composition, nutraceutical composition or food supplement composition, although the core composition is most preferably a pharmaceutical composition. Suitably, the core composition is a pharmaceutical composition comprising at least one active and one or more pharmaceutically acceptable excipients or carriers. The core composition can be any known pharmaceutical composition, whether in liquid or solid particle form. However, the pharmaceutical composition can be composed of active ingredients or is substantially composed of active ingredients.

[0343] Suitably, the active ingredient is heat sensitive. Suitably, the active ingredient is susceptible to decomposition at 200°C or above, suitably at 150°C or above, suitably at 100°C or above, suitably at 60°C or above. Such decomposition is suitably discernible by techniques known in the art, such as DSC.

[0344] The core composition is suitably or comprises a liquid, solid or gelled composition.

[0345] The liquid core composition may be a suspension (including nanosuspensions), an emulsion, a dispersion (including colloidal dispersions), etc. and may therefore include particulate solids. Alternatively, the liquid core composition may be a solution comprising the active ingredient.

[0346] The solid core composition is suitably a granular solid composition. Granular solids may include powders, granules and pellets, although most preferably, the solid particle core composition comprises or consists of a powder or granules. Other forms of granular solids that may be used are flakes, crystals, cubes, etc.

[0347] The average particle size of the solid particle core composition may suitably be greater than or equal to 10 nm, suitably greater than or equal to 100 nm, suitably greater than or equal to 1 μm, suitably greater than or equal to 10 μm, suitably greater than or equal to 100 μm, suitably greater than or equal to 200 μm. The average particle size of the solid particle core composition may suitably be less than or equal to 1000 μm, suitably less than or equal to 500 μm, suitably less than or equal to 400 μm, suitably less than or equal to 100 μm, suitably less than or equal to 1 μm. In a particular embodiment, the average particle size of the solid particle core composition is between 1 μm and 10 μm. In a particular embodiment, the average particle size of the solid particle core composition is between 50 μm and 300 μm, suitably between 60 μm and 250 μm, more suitably between 70 μm and 200 μm, most suitably between 80 μm and 190 μm.

[0348] The solid core composition can thus be a "bound" or "unbound" particulate solid. Although dispensed as a particulate solid, after dispensing, the core composition can become or otherwise transform into a solid monolithic core within a shell, with the core received in the shell. Such a transformation to a monolithic core can be caused by the addition of a binder (e.g., where additional core composition precursors or reactants are used) or other such agents that can bind the particles together to form a "bound" particulate solid. In some embodiments, the solid core composition is an unbound particulate solid within a shell.

[0349] An advantage of the core-shell arrangement provided by the process of the present invention is that it allows a high loading of active ingredients in the core. Thus, the core or core composition may comprise one or more active ingredients at a concentration of greater than or equal to 1 wt%, suitably greater than or equal to 10 wt%, suitably greater than or equal to 30 wt%, suitably greater than or equal to 50 wt%, suitably greater than or equal to 80 wt%.

[0350] Solid dosage form packaging

[0351] The solid dosage forms of the present invention can be packaged by any of a variety of methods well known in the art. For example, in the case where a pharmaceutical solid dosage form according to the present invention is produced via a printing device located in a pharmacy (e.g., to provide customized medications to patients on demand), a pharmacist can package the solid dosage form in a variety of ways, including in tablet bottles, or even monitored dosing systems, which can then be dispatched to hospitals, nursing homes, and the like for ultimate distribution to patients.

[0352] In some embodiments, the packaging can be formed by the same printing device or by different printing devices. In some examples, the packaging and the solid dosage form can be produced simultaneously, whereby the printing operation uses one or more filaments associated with the solid dosage form and one or more filaments associated with the packaging, and the packaging can be built around the solid dosage form during printing.

[0353] Preparation of shell silk

[0354] The shell filaments are suitably prepared by any of the methods described in WO2016 / 038356 (by the present applicant). Example

[0355] The present invention will now be further described by way of the following non-limiting examples. Specifically, the examples show that a wide variety of solid dosage forms can be feasibly produced by printing a partial shell, dispensing a solid or liquid into the shell, and sealing the shell. Therefore, it should be understood that the present invention is by no means limited to the specific exemplary compositions or equipment described, and that these concepts are broadly applicable to many embodiments.

[0356] equipment

[0357] Two basic types of equipment for printing shells and dispenser cores can be found in Figure 1 As explained in .

[0358] Figure 1 is a schematic diagram of a dual FDM 3D printer adapted to accommodate a) a liquid dispenser in conjunction with an FDM 3D printer head or b) a powder / granule / pellet dispenser.

[0359] Figure 1 (a) depicts a fused filament fabrication (FFF) 3D printer that has been modified. The printer has an FFF print nozzle (i.e., a structural shell print nozzle) equipped with a nozzle, a movable extruder, gears, and other standard 3D print nozzle components; a syringe (i.e., a non-structural core dispenser) that replaces the second FFF print nozzle previously installed in the printer; and a build platform. The device can be operated via a computer to print an open shell (as described in the build position) with a shell print filament passing through the FFF print nozzle, and then to fill the empty open shell with a liquid core composition dispensed from the syringe. The "filled shell" can then be closed with additional shell print filament, which can be printed on top of the "filled shell".

[0360] Figure 1 (b) depicts the Figure 1 (a) The same apparatus except that the liquid dispensing syringe is replaced by a hopper equipped with an electronically operated lower valve (i.e., tap). Such apparatus is similar to Figure 1 (a) may be operated in a similar manner, except that instead of dispensing liquid, the filled shell is then filled with Figure 1 The granular solids loaded into the hopper are distributed into the open shell through the electrically operated lower valve before being closed in the same manner as set out in (a).

[0361] The above device is essentially formed by a dual-head 3D printer that is modified by replacing the second FDM print head with either i) an extrusion head (a syringe pressure controller based on an open source design) or ii) a built-in powder dispenser.

[0362] Figure 2A dual FDM 3D printer adapted to accommodate a liquid dispenser in conjunction with an FDM 3D printer head is shown and is further illustrated by an image of a basic core-shell structure and connecting arrows between the associated prints, the component being configured to print each portion of the core-shell structure.

[0363] Example 1 - Preparation of Dipyridamole Solution (Core Composition)

[0364] A model drug, dipyridamole, was selected to test the suitability of this system to provide immediate and extended drug release. Its fluorescent color and easy detectability allowed focus on the development process. Initially, dipyridamole solutions with different solvent systems were optimized, as shown in Table 1. It has been determined that drug solution PEG 400 (10 mg / ml) is the maximum concentration that can be easily prepared.

[0365] Table 1. Optimization of highly concentrated dipyridamole solutions for liquid capsule feeding.

[0366] preparation Concentration (mg / ml) result Dipyridamole + water 20 Slightly soluble Dipyridamole + ethanol: water (20:80). 20 Slightly soluble Dipyridamole + Peg 400 20 Not completely dissolved Dipyridamole + Peg 400: Ethanol 5 Soluble Dipyridamole + Peg 400 10 Soluble

[0367] Example 2 - Preparation of Shell Silk (Shell Composition)

[0368] To design the shell, a methacrylic acid polymer with enteric properties (pH threshold>5.5) was used. EudragitL 100-55, TEC and talc were used in a ratio of 50:16.66:33.33, respectively. The physical mixture was extruded using HME at a feed temperature of 135°C and an extrusion temperature of 125°C. The nozzle size was 1 mm to allow the filament to expand to about 1.65 mm after extrusion. A similar procedure for preparing suitable printing filaments is outlined in the examples of WO2016 / 038356.

[0369] Example 3 - Dosing accuracy of liquid extruder

[0370] To assess the precision of dosing, the weight of the dispensed solution was assessed in six replicates in the order of filling a constant shape (Table 2).

[0371] Table 2 Repeatability test for liquid dispenser head

[0372]

[0373] Example 4 - 3D Printing of Enteric Liquid Capsules

[0374] The 3D printing of liquid capsules is performed using the liquid dispensing device described above and Figure 1 Schematically shown in (a) - i.e. using a dual FDM 3D printer, where one of the print heads is replaced by a liquid or semi-solid extruder. The dipyridamole solution is loaded into the extruder, and the filament is loaded into a conventional FDM head.

[0375] Figure 3 Shown is a portion of a dual FDM 3D printer adapted to accommodate a liquid dispenser (right) in conjunction with an FDM 3D printer head (left).

[0376] Table 3 - 3D printing parameters for both shell filament and core distribution

[0377]

[0378] Table 4 - Tablet sizes for shell and liquid core

[0379] X(mm) Y(mm) Z(mm) core 8.00 3.16 1.50 shell 18.38 8.00 7.45

[0380] Table 5 - Position of shell and core during the liquid capsule printing process

[0381] X(mm) Y(mm) Z(mm) core -101.11 -45.07 3.50 shell -101.11 -45.07 0.00

[0382] Example 5—In vitro dissolution test

[0383] In vitro dissolution studies were performed manually in a USPII dissolution tester. Samples were taken at 15 minute intervals for 4 hours. This was filtered through a 0.2 μm filter and analyzed using HPLC. By adding trisodium phosphate buffer, the pH of the medium was from 1.2 to 6.8 after 2 hours.

[0384] HPLC parameters

[0385] Agilent Technology 1200 Series HPLC system was also used for dipyridamole analysis. Randomly selected tablets were placed in a 500 ml volumetric flask containing 250 ml of HPLC water. This was sonicated for 2 hours, then 250 ml of acetonitrile was added, and further sonicated for 30 minutes, cooled and filtered before analysis. The HPLC system included an XTerra RP 18 4.6x150 mm, 5 μm column (made in Ireland), which was maintained at 40°C. The mobile phase included phosphate buffer at pH 6.8 and acetonitrile (60:40) at a flow rate of 1 ml / min. The injection volume was 10 μl, and the maximum run time for the assay was 10 minutes. 282 nm was the assay wavelength.

[0386] Figure 4 It is a figure showing the time course of dipyridamole release from Eudragit L-based capsules filled with drug suspensions. Drug release can be controlled during the acid phase of the experiment (2 hours). After the pH change, the model drug begins to release after 30 minutes, which shows the proof of concept of making enteric soft capsules based on this technology.

[0387] It has been determined that higher drug content can be included by using a drug suspension rather than a drug solution. In the next step, a dipyridamole suspension is used in a liquid dispenser so that higher drug concentrations can be used in the system.

[0388] Example 6 - Preparation of Dipyridamole Suspension as Feed Solution for Liquid Dispenser

[0389] Dipyridamole 1500 mg was suspended in distilled water (5%) and sonicated for 10 minutes. This was then ground using an UltraTurrax Homogeniser at 25000 rpm for 1 hour. Methocel E4 (0.5%) was added to the sample and then probe sonicated for 1 hour at 15 minute intervals in an ice bath. The size of the microparticles was studied using a Mastersizer.

[0390] Note: After size reduction using Ultra Turrax, add Methocel E4 to reduce foaming.

[0391] Using PVP as a suspending agent produces larger particles.

[0392] Table 6 - Size reduction, homogenization and general preparation conditions

[0393] Size reduction technology Time (minutes) Size(μm) span Homogenization 60 9.461 3.193 Probe Acoustic Treatment 60 5.877 2.013

[0394] Reducing the particle size to less than 6 microns significantly slows the sedimentation rate of the drug. It is expected that the use of nanosuspensions may allow even better precision.

[0395] Example 7 - Dosing accuracy and the difference between theoretical and actual volumes for single and double FDM printing Relationship

[0396] This was done using a theoretical cubic shape as an object with the dimensions described below. This will enable the theoretical volume to be related to the actual volume obtained using different nozzle sizes (0.25mm, 0.41mm and 0.84mm).

[0397] Table 7 - Theoretical volumes of cubic objects for controlling liquid dispensers.

[0398] Cube size (mm) <![CDATA[Theoretical volume (mm 3 )]]> Theoretical volume (ml) 6.21 240 0.24 5.85 200 0.2 5.43 160 0.16 4.93 120 0.12 4.31 80 0.08 3.42 40 0.04 2.71 20 0.02 2.15 10 0.01

[0399] In order to establish the relationship between the theoretical volume and the actual suspension volume dispensed, a number of calibration curves with different nozzle sizes were plotted.

[0400] Obviously, the volume dispensed can be controlled by controlling the theoretical volume of liquid dispensed in the printer software ( Figure 5 ). This was achieved across 3 different nozzle distributors. Also note that when dual printing is used, linearity is maintained ( Figure 6). However, when double printing was used, the volume dispensed decreased slightly ( Figure 7 ). This may be related to the variation in pressure applied to the syringe during coordination with the head of the FDM printer.

[0401] Figure 5 Calibration curves showing actual volume versus theoretical volume printed using a single head with (a) 0.25 mm, (b) 0.41 mm or (c) 0.84 mm nozzle size are shown. This demonstrates the possibility of controlling the dose with different nozzle sizes.

[0402] Figure 6 Calibration curves of actual volume versus theoretical volume are shown for dual print heads using (a) 0.25 mm, (b) 0.41 mm, or (c) 0.84 mm nozzle sizes.

[0403] Figure 7 The relationship between the actual volumes of single and double prints from (a) 0.25 mm, (b) 0.41 mm, or (c) 0.84 mm nozzles is shown.

[0404] Example 8 - Example of controlling the dosage of liquid capsules by 3D printing

[0405] The optimized liquid suspension was used as feed for manufacturing 3D printed enteric capsules. In this example, the capsules for enteric liquid capsules contained a suspension of dipyridamole. Three different doses of dipyridamole were tried.

[0406] Enteric shells were prepared using Eudragit L55-100 and as detailed previously in the section. The printing parameters are detailed in Table 5.

[0407] Table 8 Printing parameters for dual 3D printing of enteric-coated capsules

[0408]

[0409]

[0410] Table 9 The core dimensions of the tablets have been modified to encapsulate different volumes (doses) of drug

[0411]

[0412] It is also necessary to position the core (liquid) in an elevated position to allow the formation of a shell with walls of "significant" height in order to contain the poured liquid (Table 8).

[0413] Table 10 Positioning of capsule shell and core

[0414] X(mm) Y(mm) Z(mm) core -101.11 -45.07 2.50 shell -101.11 -45.07 0.00

[0415] Example 9—In vitro release studies

[0416] UV spectrophotometric analysis

[0417] In vitro dissolution studies were performed using a USPII dissolution tester. Samples were automatically taken out at 5 minute intervals and analyzed by HPLC as detailed below. The pH of the medium was varied from 1.2 to 6.8 after 2 hours by adding trisodium phosphate buffer.

[0418] HPLC analysis:

[0419] Agilent Technology 1200 Series HPLC system was also used for dipyridamole analysis. Randomly selected tablets were placed in a 500 ml volumetric flask containing 250 ml of HPLC water. This was sonicated for 2 hours, then 250 ml of acetonitrile was added, and further sonicated for 30 minutes, cooled and filtered before analysis. The HPLC system included an XTerra RP 18 4.6x150 mm, 5 μm column (made in Ireland), which was maintained at 40°C. The mobile phase included phosphate buffer at pH 6.8 and acetonitrile (60:40) at a flow rate of 1 ml / min. The injection volume was 10 μl, and the maximum run time for determination was 10 minutes. 282 nm was the determination wavelength.

[0420] Figure 8 The in vitro release of dipyridamole from Eudragit L-based capsules filled with different loadings of drug suspension is shown. The gastroresistant properties can be maintained without drug release in acid and without extended release in gastric media pH. This example provides proof of concept for manufacturing enteric polymers with the potential to control dosage to suit specific patients.

[0421] Example 10 - 3D printing of rapid-release liquid capsules

[0422] To demonstrate the feasibility of making immediate-release liquid capsules using this technology, the capsules were manufactured using the same dipyridamole suspension but with filaments made from an immediate-release polymer (Eudragit E) that is highly soluble in acidic media.

[0423] A mixture (10 g) consisting of 45% Eudragit E po, 5% triethyl citrate and 50% talc was physically mixed and then fed into a hot melt extruder at 100° C. It was allowed to mix for 5 minutes and then extruded at 90° C. A 1.5 mm nozzle was used on the extruder and a torque of 0.4 N was used for extrusion.

[0424] Preparation of dipyridamole suspension (as described in previous examples)

[0425] Table 11 Printing parameters for dual 3D printing of immediate release capsules

[0426]

[0427] Table 12 The core dimensions of the tablets have been modified to encapsulate different volumes (doses) of drug

[0428]

[0429] Table 13 Positioning of capsule shell and core

[0430] X(mm) Y(mm) Z(mm) core -101.11 -45.07 2.50 shell -101.11 -45.07 0.00

[0431] Fig. 9 The release profile of dipyridamole from the immediate release capsule is shown. It is evident that 100% of the drug release is achieved within 15 minutes of introduction into the acidic medium, thus meeting the pharmacopoeial standards for immediate release capsules. The drug dose of the drug can also be controlled by modifying the volume of the dispensed volume via the printer software scale command.

[0432] Other embodiments

[0433] Example 11 - Example of a liquid capsule containing a controlled dose of a drug suspension

[0434] In this example, an immediate release capsule was produced. The capsule was filled with a suspension of the model drug dipyridamole. Using computer-assisted software, the dose of dipyridamole can be controlled by controlling the volume dispensed using different designs for the core.

[0435] Preparation of shell silk

[0436] In order to prepare the shell, Eudragit EPO or RL silk without API is produced by HAAKE MiniCTW hot melt compounder (hotmelt compounder) (Thermo Scientific, Karlsruhe, Germany). The powder mixture containing polymer, plasticizer (TEC) and filler (talcum) of the optimized ratio is gradually added to HME, and allowed to mix for 5 minutes at 80rpm to allow uniform distribution of the molten material. Then, the silk is extruded at 20rpm. The processing parameters for hot melt extrusion are shown in Table 14.

[0437] Preparation of liquid core

[0438] Two liquid model cores (active aqueous solutions or suspensions) were prepared for use in syringe dispensers:

[0439] The dipyridamole suspension was initially prepared by sonicating an aqueous dipyridamole suspension of 1.5 g / 30 mL. Size reduction was achieved by initially applying a T8.01 Ultra Turrax Homogeniser (IKA, Germany) at 25,000 rpm. This was continued for 1 hour at 15 minute intervals, with a 5 minute cooling time between intervals. Methocel E4 (0.5% w / v) was added to the suspension, followed by probe sonication using a Sonics Vira cell (USA) at 15 minute intervals in an ice bath for another 4 hours at 70% amplitude. The final suspension was diluted with Methocel E4 (0.5% w / v) to achieve a drug concentration of 1.50 w / v. The size distribution of dipyridamole particles in the suspension was confirmed by using a Mastersizer 2000 laser diffractometer (Malvern Instruments, UK).

[0440] Modifications for Dual FDM 3D Printing

[0441] To fully automate the fabrication of the liquid capsules, a Makerbot replicator Experimental 2X dual FDM 3D printer (MakerBot Industries, New York, USA) was modified to dispense liquids. The right extruder of the 3D printer was replaced by a syringe-based liquid dispenser, such as Figure 1 The design for the paste extruder was obtained from an open source website and 3D printed using an M2 Makergear FDM 3D printer (Makergar, LLC, Ohio, US).

[0442] Design and printing of liquid capsules

[0443] The shell was designed as 1.6 mm thick capsules with different sizes as shown in Table 15. Since the liquid core will be dispensed and will take the shape of the shell cavity, the core of the tablet was designed as a cube to simplify the control of the dispensed volume by varying the cubic volume. For the manufacture of liquid capsules, two different printing modes were used:

[0444] a. Single-stage printing: In the Makerbot Desktop software (MakerBot Industries, New York, USA), the core was placed in the center of the cavity of its corresponding shell and printed by interchanging the shell filament and core liquid.

[0445] b. Multi-stage printing:In Simplify3D software, the shell is designed to include a complementary bottom and lid. The liquid capsule printing is performed in three stages: i) printing of the bottom, ii) filling of the liquid, and iii) sealing of the bottom in a separate 3D printing stage.

[0446] Liquid capsules for both modes were printed with cube sizes corresponding to 80 μL, 120 μL, 240 μL, or 320 μL (Table 15). The software settings were modified, and the parameters for the 3D printing of the shell were printed as shown in Table 14. The resolution was set to medium (200 μm layer thickness), the filling was 100%, and the internal and external filling patterns were set to grid and concentric circles, respectively. The outline overlap was set to 90%, and the rest were set to default settings. The software script was also modified to prevent priming of the liquid dispenser to reduce waste and because priming is not required for liquids.

[0447] Fig.10 Renderings and photographs of liquid capsules made of immediate release shells (Eudragit E shells) and filled with a microsuspension of dipyridamole (1.5% w / v) are shown.

[0448] Table 14 - Shell silk preparations and their HME and 3D printing processing parameters

[0449]

[0450] Table 15 - Theoretical volume dimensions of core and shell and weights of estimated and actual doses

[0451]

[0452] In vitro dissolution testing

[0453] In vitro drug release studies of all liquid capsules used in this study were performed in triplicate at 37 ± 0.5 °C in appropriate dissolution media at a paddle speed of 50 rpm.

[0454] Eudragit EPO-dipyridamole liquid capsule release study uses Erweka DT 600 dissolution tester (USPII) to study.The medium used is 900mL of 0.1M HCl.4 milliliters of aliquots use 5mL Leur-Lok syringes, manually collect at time intervals of 0, 5 minutes, 10 minutes, 15 minutes, 20 minutes, 25 minutes, 30 minutes, 40 minutes and 60 minutes, and filter through Millex-HA 0.45-μm filter.Each aliquot taken out replaces with 4mL of 0.1MHCl.Analyze using the HPLC method reported in Section 2.11.

[0455] Fig.11is a graph showing the effect of single and alternating printing modes from a liquid dispenser using a 2 mL syringe.

[0456] Fig.12 is a graph showing the effect of single and alternating printing modes from a liquid dispenser using a 10 mL syringe.

[0457] Fig.13 is a graph showing the linear relationship between a theoretical volume calculation based on a designed volume and an actual dose obtained via 3D printing.

[0458] Fig.14 Shown is the in vitro immediate release profile of dipyridamole suspension from 3D printed liquid Eudragit EPO capsules in gastric medium (pH 1.2) using USPII at different core volumes.

[0459] The above experiments demonstrate the possibility of controlling the liquid dosage in the capsule based on the immediate release shell and the liquid suspension. The dosage can be easily changed by only changing the volume dispensed. Although both the single-stage printing mode and the multi-stage printing mode allow adequate control of the dosage, the dual / multi-stage printing mode provides less troubleshooting and gives a higher success rate.

[0460] Example 12 - Experiments using different shell printing methods

[0461] The same capsule design (Eudragit E) as according to Example 11 was filled with the dipyridamole suspension. During the printing of the capsule shell, two printing modes were tested.

[0462] Fig.15 Shown are SEM images of the top of shells produced by two different filling patterns: a) concentric filling and b) rectangular filling.

[0463] Capsules formed via concentric filling are much more effective in controlling liquid content and preventing leakage than rectangular filling designs.

[0464] Example 13 - Exemplary Liquid Capsules Containing Drug Solutions in Both Immediate Release Shells and Extended Release Shells

[0465] In this example, the core composition is a drug solution (rather than a drug suspension according to the previous examples), and is shown to be suitable for both immediate and extended release systems.

[0466] Capsules were prepared according to Example 11 with the shell materials shown in Table 14. Eudragit RL was used for the extended release shell.

[0467] Theophylline solution was prepared by adding 15 g of citric acid and 1.5 g of Tween 80 to a 4% w / v aqueous suspension of theophylline (50 mL). It was heated to 65°C and stirred until a complete solution was formed. Methocel E4 was then added to achieve a Methocel solution concentration of 0.25% w / v, followed by cooling in an ice bath.

[0468] In vitro dissolution testing

[0469] Eudragit EPO-theophylline liquid capsule release study was carried out using AT 7Smart dissolution USPII equipment (Sotax, Switzerland), which was equipped with an online UV / VIS spectrophotometer (PG Instruments Limited, UK). The medium used was 900 mL of 0.1 M HCl. The amount of theophylline released was determined at intervals of 5 minutes at a wavelength of 272 nm and a path length of 1 mm. Data were analyzed using IDISis software (Automated Lab, 2012). For Eudragit RL 100-theophylline liquid capsules, 750 mL of simulated gastric fluid (0.1 M HCl, pH 1.2) was used to test for 2 hours, followed by exposure to pH 6.8 phosphate buffer for 12 hours. This was carried out using AT 7Smart dissolution USPII equipment.

[0470] Fig.16 Shown is the release profile of theophylline-core-capsules produced with immediate release shells containing Eudragit EPO.

[0471] Fig.17 The release profile of theophylline-core-capsules produced with extended release shells containing Eudragit RL 100 is shown.

[0472] This example demonstrates the possibility of producing liquid capsules containing drug solutions and also demonstrates the flexibility of the present invention to provide both immediate and extended release profiles.

[0473] Example 14 - Exemplary capsules containing particles

[0474] In this example, we demonstrate the ability of a modified FDM 3D printer to produce capsules while the second nozzle is equipped with a tightening valve to control the particle flow. The tightening valve can be opened and closed in a coordinated manner to allow the filling of the capsule. Theophylline particles (25%) were prepared as a model powder. The shell of the capsule was made of Eudragit E and Eudragit L100-55 for immediate release and delayed release, respectively.

[0475] Modification of HyrelSDS Fastening Valve Head

[0476] The funnel is attached to a flexible tube and mounted on a fastening valve to replace the need for a syringe head, as the powder flow will be caused by gravity. A nozzle is attached to the other end of the tube for more accurate distribution. This is then connected to an SDS head from a Hyrel 3D M30 modular 3D printer (Hyrel 3D, GA, US) to control distribution.

[0477] Preparation of theophylline granules

[0478] Theophylline (250 g), lactose monohydrate (240 g), PVP K90 (10 g) and about 30 ml of water were mixed using a planetary agitator for about 15 minutes. Granulation was performed manually using a 1 mm sieve size, and the product was dried in an oven at 70 ° C until no weight loss due to moisture was observed. The final product was passed through a 1 mm sieve, and large particles were reduced in size. The sieve sizes of 710 μm, 500 μm, 315 μm, 250 μm, 180 μm and 90 μm were used to perform a size distribution experiment on the particles.

[0479] Optimization of particle size for powder dispensing

[0480] Particles of different size ranges are fed into the hopper. The powder flow is caused by gravity, which is then controlled by a tight valve.

[0481] Using three groups of particles of the following sizes: 710-1000 μm, 500-710 μm and 315-500 μm, the flow was blocked due to the inner diameter of the tube used. The size range of 315-180 μm had similar problems, but to a lesser extent. The following size range (180-90 μm) produced the best flow and control using a tight valve.

[0482] Dispensing accuracy of powder dispensers

[0483] Particles with a particle size of 180-90 μm were fed into the powder dispenser, and solid objects with the sizes shown in Table 16 were selected as printed objects. The volume of the object was changed, and the dispensed powder was collected and weighed. A calibration curve was plotted.

[0484] Table 16 Dimensions, volumes and corresponding capsule volumes of the square object design after the 3D printing process

[0485]

[0486] Fig.18 A calibration curve for a powder dispenser (pinch valve) is shown.

[0487] Preparation of filaments for FDM 3D printing

[0488] Eudragit EPO or Eudragit L100-55 was mixed with triethyl citrate and talc (45:5:50) and then fed into a hot melt extruder at 100° C. and 130° C., respectively. Mixing was continued for about 5 minutes and then extruded at 10° C. below the feed temperature. A 1.7 mm nozzle was used during extrusion.

[0489] 3D printing of capsules

[0490] 3D printing of the capsules was performed using a Hyrel system 30M, which has multiple heads for 3D printing. One of the heads was equipped with an FDM head, and the other head was a modified head for a powder dispenser. A multi-stage printing mode was used for printing, where the bottom of the capsule was printed before powder filling and final sealing of the capsule. Shell printing was performed at 135°C and 170°C for Eudragit EPO and L100-55. Powder dispensing was performed at room temperature.

[0491] In vitro release studies.

[0492] This was performed using a USPII dissolution tester. The paddle rotation was 50 rpm and the temperature of the 0.1 N HCL dissolution medium was set to 37°C. For Eudragit RL 100 based capsules, the medium pH was changed to 6.8 after 2 hours and then to 7.4 after 6 hours.

[0493] Fig.19 Theophylline particles are shown in Immediate Release In vitro dissolution profile of 3D printed capsules in USPII dissolution test in gastric medium (0.1 M HCl).

[0494] Fig. 20 Shows 3D printed filled with theophylline particles Delayed release In vitro dissolution profile of enteric-coated capsules in gastric medium (0.1 M HCl).

[0495] This disclosure also relates to the following items:

[0496] 1. An apparatus for preparing (or printing) a solid dosage form, the apparatus comprising:

[0497] 3D printers; and

[0498] a build platform on which the solid dosage form is printable; and

[0499] a computer for controlling the 3D printer and optionally also the building platform;

[0500] Wherein the device comprises or is otherwise associated with:

[0501] a structure printing nozzle for printing a predefined three-dimensional shell comprising a shell composition onto the build platform; and

[0502] A non-structured dispenser for non-structured dispensing of a core composition into the shell; wherein the non-structured dispenser is unheated, or is otherwise associated with a temperature control element configured to maintain the temperature of the non-structured dispenser (and suitably its contents) at or below 60°C.

[0503] 2. An apparatus as described in item 1, wherein the non-structural dispenser is operable to dispense liquids and / or granular solids in a metered manner.

[0504] 3. Apparatus as claimed in any preceding clause, wherein the apparatus is operable under computer control to coordinate the metered dispensing of each dose of the core composition (or a precursor thereof) with the printing of the shell composition.

[0505] 4. The apparatus of any preceding clause, wherein the non-structural distributor is configured for dispensing granular solids.

[0506] 5. Apparatus as described in item 4, wherein the non-structural dispenser comprises a hopper and an outlet valve, the outlet valve being operable to dispense a metered amount of granular solids.

[0507] 6. Apparatus as described in any one of items 1 to 3, wherein the non-structured dispenser is configured for dispensing a liquid (suitably comprising a suspension, an emulsion, a dispersion).

[0508] 7. The apparatus of item 6, wherein the non-structural dispenser comprises a syringe operable to dispense a metered amount of liquid.

[0509] 8. The apparatus of any preceding clause, wherein the structured printing nozzle and the non-structured dispenser are both incorporated into the 3D printer.

[0510] 9. The apparatus of any preceding item, wherein the 3D printer is a fused filament fabrication (FFF) 3D printer, and the structure printing nozzle is configured to print the shell with a shell printing filament comprising the shell composition (or a precursor thereof).

[0511] 10. The apparatus of item 9, wherein the structure printing nozzle is a heatable nozzle configured to operate at a temperature between 60°C and 350°C.

[0512] 11. The apparatus of item 1, wherein:

[0513] The non-structural dispenser is operable to dispense liquids and / or granular solids in a metered manner at a temperature at or below 60°C; and

[0514] The structure printing nozzle is configured for printing a shell printing filament comprising the shell composition (or a precursor thereof) at a temperature between 60°C and 350°C.

[0515] 12. A method of preparing a solid dosage form comprising a core and a three-dimensional shell surrounding the core, the method comprising:

[0516] printing the three-dimensional shell on a build platform via a structure printing nozzle, the three-dimensional shell comprising a shell composition (or a precursor thereof); and

[0517] The core composition (or a precursor thereof) is dispensed into the three-dimensional shell via a non-structured dispenser, wherein the non-structured dispenser is not heated or otherwise associated with a temperature control element configured to maintain the temperature of the non-structured dispenser (and suitably its contents) at or below 60°C.

[0518] 13. The method for preparing a solid dosage form according to item 12, comprising:

[0519] printing a predefined three-dimensional open shell comprising a shell composition (or a precursor thereof) onto a build platform;

[0520] dispensing a core composition (or a precursor thereof) into the open shell to produce an open core-containing shell;

[0521] The open core-containing shell is closed by printing a closure on the open core-containing shell.

[0522] 14. A method as described in item 12 or 13, wherein the core composition (or its precursor) is or comprises a liquid and / or a granular solid and is dispensed into the shell in a metered manner at a temperature at or below 60°C.

[0523] 15. The method of any one of items 12 or 14, wherein the shell is printed via a fused filament fabrication printing nozzle (i.e., a structure printing nozzle) operating at a temperature between 60°C and 350°C, using a shell printing filament comprising the shell composition (or a precursor thereof).

[0524] 16. A method as described in item 12 or 13, wherein the core composition (or its precursor) is a liquid and / or a granular solid or comprises a liquid and / or a granular solid and is dispensed into the shell in a metered manner at a temperature of 60°C or below; and the shell is printed via a fused filament fabrication printing nozzle (i.e., a structure printing nozzle) operating at a temperature between 60°C and 350°C, using a shell printing filament comprising the shell composition (or its precursor).

[0525] 17. The method according to any one of items 12 to 16, wherein the method is performed using an apparatus according to any one of items 1 to 11.

[0526] 18. A solid dosage form obtainable by the method of any one of items 12 to 17.

[0527] 19. A solid dosage form comprising a core and a three-dimensional 3D printed shell surrounding the core;

[0528] in:

[0529] The shell comprises a shell composition comprising (or formed from) a 3D printing composition; and

[0530] The core comprises a core composition comprising a pharmaceutically active ingredient, a nutritionally active ingredient, or a food supplement active ingredient, wherein the core composition is contained by the shell.

[0531] 20. A solid dosage form as described in item 18 or 19, wherein the shell has a 3D printed layer structure and the core has a non-layered structure.

[0532] 21. A solid dosage form as described in any of items 18 to 20, wherein the core is physically separated from the shell and is physically movable in the shell in the presence of free internal space.

[0533] 22. A solid dosage form as described in any of items 18 to 21, wherein the core composition is a pharmaceutical composition comprising at least one pharmaceutical active and one or more pharmaceutically acceptable excipients or carriers.

[0534] 23. A solid dosage form as described in claim 22, wherein at least one of the drug actives is or includes a thermosensitive biopharmaceutical.

[0535] 24. The solid dosage form of any one of items 18 to 23, wherein the core composition is a particulate solid composition having an average particle size greater than or equal to 10 nm and less than or equal to 1000 μm.

[0536] 25. A solid dosage form as described in any of items 18 to 24, wherein the core composition is a liquid composition, optionally including some particulate material (e.g., according to a suspension, emulsion, dispersion).

[0537] 26. A solid dosage form as described in any of items 18 to 25, wherein the shell composition comprises 3D-printed shell filaments (ie, filaments used for fused filament fabrication).

[0538] 27. A solid dosage form as described in any one of items 18 to 26, wherein the shell comprises one or more having a glass transition temperature (Tg) greater than or equal to 30°C and less than or equal to 100°C. g ) shell polymer.

[0539] 28. The solid dosage form of claim 27, wherein the shell comprises or consists of:

[0540] 10 wt % to 90 wt % shell polymer;

[0541] and optionally:

[0542] 1 wt% to 30 wt% of a plasticizer; and / or

[0543] 1 wt% to 60 wt% of filler.

[0544] 29. An apparatus, method or solid dosage form as hereinbefore defined with reference to the accompanying examples and figures.

Claims

1. A method of preparing or printing a solid dosage form comprising a core and a shell surrounding the core, the method comprising: i) Printing three-dimensional open shell; ii) dispensing a core composition or a precursor thereof into the open shell to produce an open core-containing shell; and iii) closing the open core-containing shell; in: The three-dimensional open shell includes a shell composition; The core comprises a core composition comprising a pharmaceutically active ingredient, a nutritionally active ingredient, or a food supplement active ingredient; and The core is solid, liquid or gel at standard ambient temperature and pressure.

2. The method of claim 1, wherein the shell has a 3D printed layer structure and the core has a non-3D printed layer structure.

3. The method of claim 1, wherein the method comprises printing a plurality of three-dimensional open shells on a build platform prior to dispensing any core composition or precursors thereof.

4. The method of claim 1, wherein the core composition or a precursor thereof is a fluid composition capable of flowing under gravity.

5. A method according to claim 4, wherein the core composition or a precursor thereof is a particulate solid.

6. The method of claim 5, wherein the granular solid is dispensed via a hopper, the hopper being operable to dispense a metered amount of the granular solid directly from the hopper into the open shell.

7. The method of claim 4, wherein the core composition or a precursor thereof is a liquid.

8. The method of claim 7, wherein the liquid is dispensed via a syringe, the syringe being operable to dispense a metered amount of the liquid.

9. The method of claim 1, wherein the core is a solid monolithic core.

10. The method of claim 9, wherein the core composition is a solid monolith.

Citation Information

Patent Citations

  • Preparation of medical devices by solid free-form fabrication methods

    WO1995011007A1

  • Diffusion-controlled dosage form and method of fabrication including three dimensional printing

    WO2003092633A2

  • Solid dosage form production

    WO2016038356A1